Inhibitor for interaction of YAP / TAZ and TEAD, and preparation, pharmaceutical composition and application thereof
Patent Information
- Application Number
- CN202380022797.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-06
- Filing Date
- 2023-02-21
- Publication Date
- 2024-11-12
AI Technical Summary
Abnormal activation of the Hippo-YAP pathway is prevalent in a variety of tumors, and existing treatments have limited effectiveness. Especially in diseases such as malignant pleural mesothelioma, lung cancer, liver cancer, and pancreatic ductal adenocarcinoma, significant treatment challenges exist.
Develop inhibitors of the interaction between YAP/TAZ and TEAD, and destroy the interaction between YAP/TAZ and TEAD through specific small molecule intervention, thereby inhibiting the abnormal activation of the Hippo pathway and thereby inhibiting tumor growth.
It effectively inhibits the growth and differentiation of tumor cells, improves sensitivity to targeted drugs, and provides potential treatment strategies to deal with a variety of tumors, especially in refractory tumor types, which significantly improves the therapeutic effect.
Smart Images

Figure CN118946562A_ABST
Abstract
Description
Inhibitors of the interaction between YAP / TAZ and TEAD, their preparation, pharmaceutical composition and application
[0001] Cross-references
[0002] This application claims the benefit of Chinese Patent Application No. 202210158641.4, filed on February 21, 2022, Chinese Patent Application No. 202210344511.X, filed on March 31, 2022, Chinese Patent Application No. 202210794926.7, filed on July 5, 2022, Chinese Patent Application No. 202211544166.0, filed on December 1, 2022, and Chinese Patent Application No. 202211559809.9, filed on December 6, 2022. These applications are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to inhibitors of the interaction between YAP / TAZ and TEAD, their preparation, pharmaceutical compositions and uses. Background Art
[0004] The Hippo pathway is involved in regulating cell growth, proliferation, and apoptosis, playing a crucial role in regulating organ size, cancer development, tissue regeneration, and the renewal and differentiation of stem and progenitor cells. Studies have shown that in mammals, this pathway has a tumor suppressor effect, and abnormal activation of key effector molecules in the pathway is closely associated with the development and progression of various tumors. Furthermore, the Hippo pathway interacts with other pathways, such as Wnt, Notch, Hedgehog, and MAPK / ERK, to jointly regulate cell fate. Dysregulation of this pathway also has important implications for diseases beyond cancer.
[0005] The Hippo signaling pathway is highly conserved throughout evolution. The core components of the Hippo signaling pathway in mammalian cells include a kinase chain consisting of the MST1 / 2 (member of Ste20-like kinase, whose homolog in Drosophila is Hippo) and LATS1 / 2 (large tumor suppressor 1 / 2, whose homolog in Drosophila is Warts) protein kinases, and their adaptor proteins SAV1 and Mob1 (Mps one binder kinase activator-like 1A and 1B, whose homolog in Drosophila is Mats). This kinase chain phosphorylates the transcriptional coactivators YAP (Yes-Associated Protein) and TAZ (Transcription co-activator with PDZ binding motif, also known as WWTR1) (corresponding to Yorkie in Drosophila).
[0006] LATS1 / 2, core components of the mammalian Hippo pathway, belong to the nuclear Dbf2-related (NDR) family of kinases. They are activated by binding to the scaffolding proteins Mob1A / B. LATS1 / 2 can also be directly activated by phosphorylation by MST1 / 2. LATS1 / 2 kinases phosphorylate multiple sites on the downstream effector YAP, with phosphorylation at Ser127 being crucial for YAP inhibition. YAP phosphorylated at Ser127 binds to 14-3-3 proteins in the cytoplasm, trapping it in the cytoplasm and preventing it from entering the nucleus to exert its transcriptional function, thereby inhibiting YAP's pro-proliferative and anti-apoptotic activities. Similarly, LATS1 / 2 kinases phosphorylate multiple sites on the transcription factor TAZ, with phosphorylation at Ser89 being crucial for TAZ inhibition. Phosphorylated TAZ is retained or sequestered in the cytoplasm. Furthermore, phosphorylated YAP or TAZ can be further recognized and degraded by the ubiquitinating enzyme SCFβ-TRCP. Therefore, if the Hippo pathway is "on", YAP and / or TAZ are inactivated by phosphorylation and retained in the cytoplasm. Conversely, if the Hippo pathway is "off", YAP and / or TAZ are dephosphorylated and activated and are often found in the nucleus.
[0007] YAP, as a transcription factor, does not inherently contain a DNA-binding domain. Activated YAP must bind to transcription factors after entering the nucleus to jointly exert its transcriptional function. The transcription factor to which YAP binds most strongly after entering the nucleus is TEAD. The human TEAD family of proteins includes TEAD1 / TEAD2 / TEAD3 / TEAD4. YAP, together with TEAD (or other transcription factors such as Smad1, RUNX, ErbB4, and p73), can initiate transcription of a series of downstream genes, including CTGF (connective tissue growth factor), Gli2, Birc5, Birc2, FGF1 (fibroblast growth factor 1), and AREG (amphiregulin). Like YAP, unphosphorylated TAZ enters the nucleus, where it binds to multiple DNA-binding transcription factors, such as PPARγ (peroxisome proliferation-activated receptorγ), TTF-1 (thyroid transcription factor-1), Pax3, TBX5, RUNX, TEAD1, and Smad2 / 3 / 4. Most genes activated by YAP or TAZ transcription factor complexes are related to cell growth and proliferation.
[0008] As previously mentioned, the Hippo-YAP pathway regulates organ size and normal physiological function by regulating cell proliferation and apoptosis, and is strictly regulated under normal physiological conditions. Inactivation of protein kinases in the Hippo pathway or activation of YAP promotes tumorigenesis. In fact, abnormal activation of the Hippo pathway is a major event in the development and progression of various malignant tumors. Elevated expression levels and increased nuclear localization of YAP or TAZ have been found in tumors including non-small cell lung cancer, breast cancer, head and neck cancer, esophageal cancer, ovarian cancer, liver cancer, prostate cancer, mesothelioma, and skin cancer.
[0009] Malignant pleural mesothelioma (MPM) is a rare malignant tumor of the chest with clinical manifestations that are often nonspecific and insidious. Many patients are already in the advanced stage of the disease at the time of diagnosis. The treatment options for surgically unresectable MPM are extremely limited. The current first-line pemetrexed / platinum treatment is unsatisfactory, with a median overall survival rate of only about one year, and there is a large unmet clinical need. Aberrant activation of the Hippo-YAP pathway is present in approximately 70% of MPM patients and is considered to be an important cancer driver gene. Reducing the activity of the Hippo-YAP pathway through biological means and chemical small molecules has shown good activity in inhibiting tumor growth, indicating that Hippo-YAP is a potential target for the treatment of MPM.
[0010] Lung cancer is currently one of the most deadly cancers in the world. Currently, a variety of treatments are available for lung cancer, including targeted therapies and immunotherapy, but these treatments often face challenges such as low response rates and recurrence. In recent years, numerous studies have demonstrated that the YAP signaling pathway can induce resistance to lung cancer drugs, such as EGFR inhibitors, by inducing tumor cell dormancy and resisting apoptosis. Furthermore, inhibiting the Hippo-YAP signaling pathway can increase the sensitivity of tumor cells to EGFR-targeted drugs, suggesting that a combination therapy strategy could be employed clinically to enhance therapeutic efficacy.
[0011] Liver cancer is a highly prevalent cancer in China. Current clinical treatments have seen limited breakthroughs, and there is a significant unmet clinical need. YAP is a key gene in regulating the development and progression of liver cancer. Multiple in vivo experiments have shown that overexpressing YAP alone or knocking out the upstream regulatory factors MST1-2 in the mouse liver, without the introduction of other oncogenes, can induce the development of hepatocellular carcinoma. Furthermore, in established liver cancer mouse models, knocking down YAP expression significantly inhibits tumors and promotes the differentiation of tumor cells into functional hepatocytes, accompanied by the restoration of liver function. This suggests that YAP is a potential target for the treatment of liver cancer.
[0012] KRas mutations are common in pancreatic ductal adenocarcinoma (PDAC), and targeting KRas is considered to have broad clinical application prospects in PDAC. In PDAC mouse models, targeting KRas can inhibit tumor growth, but also leads to tumor recurrence. Studies have shown that YAP plays a key role in this process by regulating Fos and inducing EMT (epithelial-mesenchymal transition). Knocking down YAP expression in recurrent tumors can re-inhibit tumor growth, suggesting that targeting YAP also has potential clinical application prospects in PDAC.
[0013] Inhibitors targeting BRAF and MEK have been widely used clinically in a variety of tumors, including melanoma, colon cancer, and thyroid cancer, but they also face challenges with resistance and recurrence. Studies have shown that Hippo-YAP, a pathway that promotes tumor cell growth, is overactivated in multiple drug-resistant tumor models. Inhibiting its activity significantly increases sensitivity to BRAF / MEK inhibitors, suggesting potential for clinical drug combination therapy.
[0014] In vitro, overexpression of YAP or TAZ in mammalian epithelial cells leads to cell transformation. Enhanced YAP / TAZ transcriptional activity induces EMT (epithelial-mesenchymal transition) and confers stem cell-like characteristics to breast cancer cells.
[0015] In summary, therapeutic strategies targeting the Hippo-Yap pathway are highly likely to provide new insights into the treatment of various tumors. The development of specific small molecules to disrupt the interaction between YAP / TAZ and TEAD, attenuating YAP transcriptional activity and thereby inhibiting the development of tumors with Hippo pathway abnormalities is expected to become a new strategy for tumor treatment and has broad clinical application prospects.
[0016] Summary of the Invention
[0017] The present disclosure provides inhibitors of the interaction between YAP / TAZ and TEAD. The present disclosure also provides methods for preparing the inhibitors, pharmaceutical compositions containing the inhibitors, and their use in treating or preventing diseases mediated by the interaction between YAP / TAZ and TEAD.
[0018] In one aspect, the present disclosure provides a compound represented by the following Formula I, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof:
[0019] Where:
[0020] X1 is selected from: O and NR a ;
[0021] X2 is selected from: C and N;
[0022] X3 is selected from: C and N;
[0023] Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2、C(R 13 )、-OCH2-、-N(R 12 )CH2-, -CH2CH2- and N(R 12 ), and Y5 and Y6 are not bonds at the same time;
[0024] Y1 and Y4 are independently selected from the group consisting of: a bond, O, N, C, S, -S(O)-, -C(O)-, -S(O)2-, CH, CH2, NH, C(R 13 )、CH(R 13 )、C(R 13 )2 and N(R 12 ), provided that Y1 and Y4, Y1 and Y5, Y4 and Y6 are not simultaneously a bond, O, S, -S(O)- or -S(O)2- and satisfy the bond valence theory;
[0025] Alternatively, when Y1, Y4 and Y6 are arbitrarily selected from C(R 13)2, two R on the same carbon atom 13 The C atom connected thereto may form a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered heterocyclic group, thereby forming a spiro ring structure with ring B;
[0026] Alternatively, the ring atoms in Y1 or Y6, the ring atoms in Y4, and the substituents attached to the ring atoms form a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, a substituted or unsubstituted 4-9 membered heterocyclic group, a substituted or unsubstituted 6-10 membered aryl group, or a substituted or unsubstituted 5-10 membered heteroaryl group, thereby forming a parallel ring structure with ring B;
[0027] Alternatively, X2 together with the ring atoms in Y6 and R 11 The connected ring atoms and the substituents connected to the ring atoms constitute a substituted or unsubstituted 5- or 6-membered cyclic hydrocarbon group, a substituted or unsubstituted 5- or 6-membered heterocyclic group, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- or 6-membered heteroaryl group, thereby forming a tricyclic structure with rings A and B;
[0028] Ring B is a 5-, 6- or 7-membered heterocyclic ring, a benzene ring or a 5-, 6- or 7-membered heteroaromatic ring; Ring B may optionally be replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R" and substituted or unsubstituted alkoxy;
[0029] R1 is selected from: cyano and -C(O)NR'R";
[0030] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0031] R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic;
[0032] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0033] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;
[0034] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; each of the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from N and O;
[0035] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0036] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0037] R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen;
[0038] R 10 is selected from: H, halogen, and substituted or unsubstituted alkyl;
[0039] R 11 is selected from the group consisting of: H, hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R", and substituted or unsubstituted alkoxy;
[0040] Each R not participating in the ring 12 independently selected from the group consisting of: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-14 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl;
[0041] Each R not participating in the ring 13 independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C6-14 aryl-S(O)2-, substituted or unsubstituted 3-6 membered cyclic hydrocarbon group-C(O)- and NR'R"-C(O)-, or two R on the same carbon atom 13 Forming oxo (=O) or thio (=S);
[0042] R 13 or R12 After participating in the ring formation, its ring atoms may be optionally substituted by 1-3 heteroatoms selected from O, N and S;
[0043] R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl;
[0044] R a Selected from H and C1-C4 alkyl;
[0045] Here, the dotted line indicates the presence or absence of a double bond.
[0046] In another aspect, the present disclosure provides pharmaceutical compositions containing a therapeutically or prophylactically effective amount of a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb, and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, which may further contain a pharmaceutically acceptable carrier or excipient.
[0047] In another aspect, the present disclosure provides a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure for the preparation of a medicament for treating or preventing diseases mediated by the interaction of YAP / TAZ with TEAD.
[0048] In another aspect, the present disclosure provides a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure for use in treating or preventing a disease. In some embodiments, the present disclosure also provides a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure for use in treating or preventing diseases mediated by the interaction of YAP / TAZ with TEAD.
[0049] In another aspect, the present disclosure provides a method for treating or preventing a disease mediated by the interaction of YAP / TAZ with TEAD, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure.
[0050] A more detailed technical solution and description of the present disclosure are as follows. DETAILED DESCRIPTION
[0051] The following specific embodiments are provided to enable those skilled in the art to more clearly understand the content of the present disclosure. It should be noted that these embodiments are recorded for illustrative purposes only and are not intended to limit the scope of protection of this application.
[0052] I. Terminology
[0053] In the following description, certain specific details are set forth in order to provide a comprehensive understanding of multiple embodiments. However, it will be understood by those skilled in the art that the technical solutions of the present disclosure can be implemented without these details. In other cases, well-known structures are not shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context otherwise requires, throughout the specification and the following claims, the wording "comprising" and its variations, such as "including" and "containing" will be interpreted in an open, inclusive sense, that is, as "including but not limited to". In addition, the titles provided herein are for convenience only and do not interpret the scope or meaning of the disclosure claimed.
[0054] Reference in this specification to "one embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, multiple appearances of the phrase "in one embodiment" in this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. In addition, as used in this specification and claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. It should also be noted that the term "or" is generally used in its sense including "and / or" unless the context clearly dictates otherwise.
[0055] Definitions of standard chemical terms can be found in the references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4TH ED." Vols. A (2000) and B (2001), Plenum Press, New York). Unless otherwise indicated, conventional methods within the skill of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods, are used. Unless otherwise specified, the terms used herein in the descriptions of analytical chemistry, synthetic organic chemistry, and pharmaceutical and medicinal chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. For example, the manufacturer's instructions for use of the kit can be utilized, or reactions and purifications can be carried out in accordance with methods well known in the art or the descriptions of the present disclosure. The above techniques and methods can generally be implemented according to conventional methods well known in the art, as described in the various general and more specific references cited and discussed in this specification. In this specification, groups and substituents thereof can be selected by those skilled in the art to provide stable structural moieties and compounds.
[0056] When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.
[0057] Certain chemical groups defined herein are preceded by a simplified notation to indicate the total number of carbon atoms present in the group. For example, a C1-C6 alkyl group refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms. The total number of carbon atoms in the simplified notation does not include carbons that may be present in substituents of the group.
[0058] When a variable is referred to in the present disclosure as "selected from: ...", it means that the variable is selected from any one of the options listed after the colon, or, where possible, it means that the variable is selected from one or more of the options listed after the colon.
[0059] All numerical ranges mentioned in this disclosure are intended to include both endpoints of the range, all integers within the range, and sub-ranges formed by these integers.
[0060] In addition to the foregoing, when used in the specification and claims of the present disclosure, the following terms have the meanings indicated below unless otherwise specifically stated.
[0061] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0062] "Hydroxy" refers to an -OH group.
[0063] "Hydroxyalkyl" refers to an alkyl group, as defined below, substituted with a hydroxy (-OH) group.
[0064] "Carbonyl" refers to a -C(=O)- group.
[0065] "Oxo" refers to a =0 group.
[0066] "Thio" refers to a =S group.
[0067] "Nitro" refers to -NO2.
[0068] "Cyano" refers to -CN.
[0069] "Amino" refers to -NH2.
[0070] "Substituted amino" refers to an amino group substituted with one or two alkyl groups, alkylcarbonyl groups, aralkyl groups, aryl groups, heteroaryl groups, heterocyclyl groups, heteroaralkyl groups as defined below, for example, monoalkylamino, dialkylamino, alkylcarbonylamino, aralkylamino, heteroaralkylamino, heterocyclylamino, heteroarylamino and arylamino groups. In some embodiments herein, "substituted amino" is represented by -NR'R", wherein R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl (provided that at least one of R' and R" is not H).
[0071] "Carboxyl" refers to -COOH.
[0072] -C(O) means -C(=O).
[0073] In the present disclosure, the term "Ci-Cj" refers to a range of carbon atoms, wherein i and j are integers, and the range of carbon atoms includes the endpoints (i.e., i and j) and each integer point between the endpoints, wherein j is greater than i. For example, C1-C6 refers to a range of 1 to 6 carbon atoms, including 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, and 6 carbon atoms. For another example, the term "C1-C12" refers to 1 to 12, particularly 1 to 10, particularly 1 to 8, particularly 1 to 6, particularly 1 to 5, particularly 1 to 4, particularly 1 to 3, or particularly 1 to 2 carbon atoms.
[0074] In the present disclosure, as a group or as part of another group (for example, as used in groups such as alkyl groups substituted with halogens (such as fluorine, chlorine, bromine or iodine)), the term "alkyl" refers to a fully saturated straight or branched hydrocarbon chain group consisting solely of carbon atoms and hydrogen atoms connected to the rest of the molecule by a single bond, having, for example, 1 to 12 (preferably 1 to 8, more preferably 1 to 6) carbon atoms. In some embodiments, the alkyl group contains 1 to 11 carbon atoms. In some embodiments, the alkyl group contains 1 to 10 carbon atoms, 1 to 9 carbon atoms, 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms or 1 to 2 carbon atoms. Non-limiting examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, tert-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Each alkyl group of each embodiment of the present disclosure is preferably a C1-C4 alkyl group. In some embodiments, the carbon chain length of the alkyl group can be 8-22 carbon atoms, preferably a fatty chain. Unless otherwise specifically provided in this specification, the alkyl group may be optionally substituted.
[0075] In the present disclosure, the term "alkenyl," as a group or part of another group, refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms with one or more carbon-carbon double bonds (-C=C-) connected to the remainder of the molecule by a single bond. In some embodiments, the alkenyl group contains 2 to 12 carbon atoms. In some embodiments, the alkenyl group contains 2 to 11 carbon atoms. In some embodiments, the alkenyl group contains 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkenyl group contains 2 carbon atoms. Non-limiting examples of alkenyl groups include ethenyl, 1-propenyl, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, Unless otherwise specifically provided in the specification, alkenyl may be optionally substituted.
[0076] In the present disclosure, as a group or part of another group, the term "alkynyl" refers to a straight or branched hydrocarbon chain group consisting solely of carbon atoms and hydrogen atoms with one or more carbon-carbon triple bonds (-C≡C-) connected to the rest of the molecule by a single bond. In some embodiments, the alkynyl group contains 2 to 12 carbon atoms. In some embodiments, the alkynyl group contains 2 to 11 carbon atoms. In some embodiments, the alkynyl group contains 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkynyl group contains 2 carbon atoms. Non-limiting examples of alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, etc. Unless otherwise specifically provided in this specification, alkynyl groups may be optionally substituted.
[0077] In the present disclosure, the term "alkoxy" as a group or part of another group refers to a "-O-alkyl" group, wherein alkyl has the meaning as described above.
[0078] In this disclosure, the term "haloalkyl" as a group or part of another group refers to an alkyl group substituted by one or more halogens, wherein alkyl has the meaning given above and the number of halogens can be up to the same number of substitutable hydrogens on the alkyl group.
[0079] In the present disclosure, the term "acyl" as a group or as part of another group refers to a monovalent radical remaining after removing the hydroxyl group from an aliphatic carboxylic acid, and can be represented by the general formula "GC(=O)-", where G represents H or an alkyl, alkenyl, or alkynyl group as described above. For example, specific examples of C1-C4 acyl groups include, but are not limited to, formyl, acetyl, propionyl, butyryl, and the like.
[0080] In the present disclosure, as a group or part of another group, the term "cycloalkyl" refers to a saturated or partially unsaturated non-aromatic monocyclic or polycyclic hydrocarbon group or moiety (moiety, representing a structural fragment of an organic molecule) consisting only of carbon atoms and hydrogen atoms and optionally having one or more carbon-carbon double bonds (-C=C-) or carbon-carbon triple bonds (-C≡C-), which can be connected to the rest of the molecule through any suitable carbon atom and includes "cycloalkyl", "cycloalkenyl" and "cycloalkynyl". In some embodiments, the cycloalkyl group contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 ring carbon atoms. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and cyclooctynyl. Unless otherwise specifically noted in this specification, the carbon atoms in the cycloalkyl may be optionally oxidized (thereby forming an oxo (=O) group), and the cycloalkyl may be optionally substituted.
[0081] In the present disclosure, as a group or a part of other groups, the term "cycloalkyl" refers to a saturated non-aromatic monocyclic or polycyclic hydrocarbon radical or part consisting only of carbon atoms and hydrogen atoms, which can be connected to the rest of the molecule via any suitable carbon atom. In some embodiments, cycloalkyl contains 3 to 12 ring carbon atoms, 3 to 10 ring carbon atoms, 3 to 9 ring carbon atoms, 3 to 8 ring carbon atoms, 3 to 7 ring carbon atoms, 3 to 6 ring carbon atoms, 3 to 5 ring carbon atoms, 4 to 12 ring carbon atoms, 4 to 10 ring carbon atoms, 4 to 9 ring carbon atoms, 4 to 8 ring carbon atoms, 4 to 7 ring carbon atoms, 4 to 6 ring carbon atoms, 4 to 5 ring carbon atoms. Non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl etc. Unless stated otherwise specifically in the specification, carbon atoms in a cycloalkyl group may be optionally oxidized (thereby forming an oxo (=0) group), and cycloalkyl groups may be optionally substituted.
[0082] In the present disclosure, as a group or part of other groups, the term "cycloalkenyl" refers to a partially unsaturated non-aromatic monocyclic or polycyclic hydrocarbon group or portion consisting only of carbon atoms and hydrogen atoms and having one or more carbon-carbon double bonds (-C=C-), which can be connected to the rest of the molecule via any suitable carbon atom. In some embodiments, the cycloalkenyl group contains 5 to 12 ring carbon atoms, 5 to 10 ring carbon atoms, 5 to 9 ring carbon atoms, 5 to 8 ring carbon atoms, 5 to 7 ring carbon atoms, 5 to 6 ring carbon atoms. Non-limiting examples of cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl, etc. Unless otherwise specifically indicated in this specification, the carbon atoms in the cycloalkenyl group can be optionally oxidized (thereby forming an oxo (=O) group), and the cycloalkenyl group can be optionally substituted.
[0083] In the present disclosure, as a group or part of other groups, the term "cycloalkynyl" refers to a partially unsaturated non-aromatic monocyclic or polycyclic hydrocarbon group or portion consisting only of carbon atoms and hydrogen atoms and having one or more carbon-carbon triple bonds (-C=C-), which can be connected to the rest of the molecule via any suitable carbon atom. In some embodiments, the cycloalkynyl contains 8 to 12 ring carbon atoms, 8 to 11 ring carbon atoms, 8 to 10 ring carbon atoms, 8 to 9 ring carbon atoms. Non-limiting examples of cycloalkynyl include cyclooctynyl and the like. Unless otherwise specifically indicated in this specification, the carbon atoms in the cycloalkynyl group can be optionally oxidized (thereby forming an oxo (=O) group), and the cycloalkynyl group can be optionally substituted.
[0084] In the present disclosure, as a group or part of other groups, the term "spirocyclyl" or "spiro ring" refers to a ring system consisting of multiple (e.g., two, three or more) rings, wherein at least two rings are cycloalkyl rings that are combined with each other to share a carbon atom. In some embodiments, the spirocyclyl contains 6 to 12 ring carbon atoms, 6 to 11 ring carbon atoms, 6 to 10 ring carbon atoms, 6 to 9 ring carbon atoms, 6 to 8 ring carbon atoms, 6 to 7 ring carbon atoms. Non-limiting examples of spirocyclyl include, but are not limited to, spiro [5.5] undecyl, spiro-pentadienyl, spiro [3.6] decyl, etc. Unless otherwise specifically provided in this specification, spirocyclyl may be optionally substituted.
[0085] In the present disclosure, the term "paracyclyl" or "paracyclyl (also known as "fused ring"), as a group or part of another group, refers to a cycloalkyl ring system consisting of multiple (e.g., two, three or more) rings, at least two of which are linked to each other by sharing two adjacent carbon atoms (i.e., the at least two rings share a covalent bond such that the bridgehead atoms are directly connected). In some embodiments, the paracyclyl contains 5 to 12 ring carbon atoms, 5 to 11 ring carbon atoms, 5 to 10 ring carbon atoms, 5 to 9 ring carbon atoms, 5 to 8 ring carbon atoms, 5 to 7 ring carbon atoms, or 5 to 6 ring carbon atoms. Non-limiting examples of cyclyl groups include, but are not limited to, 2,3-dihydroindanyl, 1,2,3,4-tetrahydro-naphthyl, 5,6,7,8-tetrahydro-naphthyl, 8,9-dihydro-7H-benzocyclohepten-6-yl, 6,7,8,9-tetrahydro-5H-benzocycloheptenyl, 5,6,7,8,9,10-hexahydro-benzocyclooctenyl, etc. Unless stated otherwise specifically in the specification, cyclyl groups may be optionally substituted.
[0086] In the present disclosure, the term "bridged ring group" or "bridged ring" as a group or part of another group refers to a ring system consisting of multiple (e.g., two, three, or more) rings, wherein at least two of the rings are cycloalkyl groups that are connected to each other by sharing three or more carbon atoms (the at least two rings are separated by two bridgehead atoms by a bridge containing at least one atom). In some embodiments, the bridged ring group contains 8 to 12 ring carbon atoms, 8 to 11 ring carbon atoms, 8 to 10 ring carbon atoms, or 8 to 9 ring carbon atoms. Non-limiting examples of bridged ring groups include, but are not limited to, bicyclo[1.1.1]pentenyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.2.1]octenyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.3]undecyl, adamantyl, and the like. Unless stated otherwise specifically in the specification, a bridged ring group may be optionally substituted.
[0087] In the present disclosure, the term "heterocyclyl" or "heterocycle" as a group or part of another group means a stable saturated or partially unsaturated non-aromatic cyclic group or moiety consisting of carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms) and heteroatoms (e.g., 1 to 6 heteroatoms, more preferably 1, 2 or 3 heteroatoms) selected from nitrogen, phosphorus, oxygen and sulfur (preferably nitrogen, oxygen or sulfur). In some embodiments, the heterocyclyl group can contain 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 ring-forming atoms, e.g., 3 to 20 ring-forming atoms, 3 to 19 ring-forming atoms, 3 to 18 ring-forming atoms, 3 to 17 ring-forming atoms, 3 to 16 ring-forming atoms, 3 to 15 ring-forming atoms, 4 to 12 ring-forming atoms, 4 to 10 ring-forming atoms, 4 to 9 ring-forming atoms, 4 to 8 ring-forming atoms, 4 to 7 ring-forming atoms, 4 to 6 ring-forming atoms, 4 to 5 ring-forming atoms. Unless otherwise specifically indicated in this specification, the heterocyclic group can be a monocyclic, bicyclic, tricyclic or more ring system, which may include a fused / annular system (i.e., an annular heterocyclic group, such as a 4-9 member annular heterocyclic group), a bridged ring system (i.e., a bridged heterocyclic group, such as a 6-12 member bridged heterocyclic group) or a spiro ring system (i.e., a spiro heterocyclic group, such as a 6-12 member spiro heterocyclic group). An annular heterocyclic group refers to a ring system of a heterocyclic group consisting of multiple (e.g., two, three or more) rings, wherein at least two rings are combined to share two adjacent atoms (i.e., the at least two rings share a covalent bond, so that the bridgehead atoms are directly connected), preferably a bicyclic annular heterocyclic group. A bridged heterocyclic group refers to a ring system of a heterocyclic group consisting of multiple (e.g., two, three or more) rings, wherein at least two rings are combined to share three or more atoms (the at least two rings are separated by a bridge containing at least one atom, and the bridgehead atoms are separated by a bridge containing at least one atom). Spiro heterocyclic group refers to a ring system of a heterocyclic group consisting of multiple (e.g., two, three or more) rings, wherein at least two rings are heterocyclic groups that are combined with a common carbon atom. The nitrogen, carbon or sulfur atom in the heterocyclic group may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic group may be connected to the rest of the molecule via a carbon atom or a heteroatom through a single bond. In some cases, the heterocyclic group may be carbon-connected, nitrogen-connected or sulfur-connected. In some embodiments, the heterocyclic group is carbon-connected. In some embodiments, the heterocyclic group is nitrogen-connected. In some embodiments, the heterocyclic group is sulfur-connected. Unless otherwise specifically provided in this specification, the heterocyclic group may be optionally substituted.
[0088] Heterocyclyl also includes groups in which a heterocyclyl group is fused to a saturated, partially unsaturated, or fully unsaturated (i.e., aromatic) cycloalkyl, aryl, heterocyclyl, or heteroaryl group. In heterocyclyl groups comprising fused rings, one or more rings may be aryl or heteroaryl as defined below. Examples of fused heterocyclic groups include, but are not limited to, phenyl-fused heterocyclic groups or pyridyl-fused heterocyclic groups, as well as quinolinyl, isoquinolinyl, quinoxalinyl, quinolizinyl, quinazolinyl, azaindolizinyl, pteridinyl, chromenyl, isochromenyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, benzofuranyl, isobenzofuranyl, benzimidazolyl, benzothiophenyl, benzothiazolyl, carbazolyl, phenazinyl, phenothiazinyl, phenanthridinyl, imidazo[1,2-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,3]triazolo[4,3-a]pyridinyl-fused heterocyclic groups, and the like.
[0089] In some embodiments, the heterocyclyl group is a stable 4- to 12-membered, 5- to 12-membered, 6- to 10-membered, 4- to 10-membered, or 4- to 9-membered non-aromatic monocyclic, bicyclic, tricyclic, or more ring group (including fused, bridged, or spirocyclic groups) containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, for example, a stable 5- to 10-membered (e.g., 4- to 9-membered) non-aromatic monocyclic, bicyclic, tricyclic, or more ring group (including fused, bridged, or spirocyclic groups) containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur. Examples of heterocyclic groups include, but are not limited to, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2,7-diaza-spiro[3.5]nonan-7-yl, 2-oxa-6-aza-spiro[3.3]heptane-6-yl, 2-oxa-6-aza-spiro[3.4]octan-7-yl, 8-oxa-2-aza-spiro[4.5]decane-6-yl, 2,5-diaza-bicyclo[2.2.1]heptane-2-yl, azetidinyl, oxetanyl, thietanyl, thia Cyclopentanyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxolane, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, dihydroindole, octahydroindole, octahydroisoindole, pyrazolidinyl, phthalimido, dioxothiomorpholinyl, dioxothiolane, dioxothietane, thiacyclohexane, dioxothiomorpholinyl, 1,4-oxathiacyclohexane and the like.
[0090] In the present disclosure, as a group or part of another group, "aryl" or "aromatic ring" refers to a conjugated hydrocarbon ring system group or part having 6 to 18 carbon atoms (e.g., 6 to 14 carbon atoms or 6 to 10 carbon atoms, such as 6, 7, 8, 9 or 10 carbon atoms). The aryl group can be a monocyclic, bicyclic, tricyclic or more ring system, and can also be fused with a cycloalkyl or heterocyclic group as defined above. In the case of a polycyclic system, although all rings can be aromatic, only one ring needs to be aromatic. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, 2,3-dihydro-1H-isoindolyl, 2-benzoxazolinone, 2H-1,4-benzoxazine-3(4H)-one-7-yl, etc. Unless otherwise specifically provided in this specification, aryl groups may be optionally substituted.
[0091] In the present disclosure, the term "heteroaryl" or "heteroaromatic ring" as a group or part of another group means a conjugated ring system group or part having carbon atoms (e.g., 1 to 15 carbon atoms, 1 to 14 carbon atoms, 1 to 13 carbon atoms, 1 to 12 carbon atoms, 1 to 11 carbon atoms, 1 to 10 carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms) and heteroatoms selected from nitrogen, oxygen and sulfur (e.g., 1 to 6 heteroatoms, more preferably 1, 2 or 3 heteroatoms) within the ring. In some embodiments, the heteroaryl group may contain 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 ring-forming atoms, such as 5 to 20 ring-forming atoms, 5 to 19 ring-forming atoms, 5 to 18 ring-forming atoms, 5 to 17 ring-forming atoms, 5 to 16 ring-forming atoms, 5 to 15 ring-forming atoms, 5 to 14 ring-forming atoms, 5 to 13 ring-forming atoms, 5 to 12 ring-forming atoms, 5 to 10 ring-forming carbon atoms, 5 to 9 ring-forming atoms, 5 to 8 ring-forming atoms, 5 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. Unless otherwise specified in the specification, the heteroaryl group may be a monocyclic, bicyclic, tricyclic, or higher ring system, and may further be fused with a cycloalkyl, aryl, or heterocyclyl group as defined above. The nitrogen, carbon or sulfur atoms in the heteroaryl group may be optionally oxidized, and the nitrogen atom may be optionally quaternized. For the purposes of this disclosure, the heteroaryl group is preferably a stable 5- to 12-membered aromatic group comprising 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 5- to 10-membered aromatic group comprising 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, or a 5- to 6-membered aromatic group comprising 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur. Unless otherwise specifically provided in this specification, the heteroaryl group may be optionally substituted.
[0092] Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzomorpholinyl, benzisodiazolyl, benzotriazolyl, benzopyrazolyl, imidazopyridinyl, pyridomorpholinyl, pyrazolopyridinyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, pyridonyl, pyrimidinonyl, pyridazinonyl, indolizinyl, isoindolyl, indazolyl, isoindazolyl, purinyl, quinolyl, isoquinolyl, naphthiazinyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridin ... pyridinyl, pyridinyl, pyridaz ...
[0093] In the present disclosure, all cyclic groups may exist as substituents on a parent core, or may themselves exist as part of a chain (including straight chain and branched) structure, a parent core or a portion of a parent core.
[0094] In the present disclosure, the term "heteroarylalkyl" refers to an alkyl group as defined above substituted with a heteroaryl group as defined above.
[0095] In the present disclosure, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0096] In the present disclosure, the term "substituted", whether or not preceded by the term "optionally" (i.e., equivalent to substituted or unsubstituted), refers to the replacement of one or more hydrogens of a specified group or portion by a "suitable substituent". Herein, the number of substituents may be one or more, i.e., 1, 2, 3, 4, 5, or 6 or more, depending on the group being substituted and the nature of the substituent. For example, when the substituent of an ethyl group is a halogen, the group may be substituted by 1, 2, 3, 4, or 5 substituents, such as trifluoromethyl, pentafluoroethyl, etc., depending on the structure of the substituted group. In some embodiments, the number of substituents is 1, 2, or 3. In some embodiments, the number of substituents is 1 or 2. In some embodiments, the number of substituents is 1. It will be understood that "substituted" or "substituted by..." includes implicit conditions, i.e., such replacement is carried out according to the allowed valence of the substituted atom, and the replacement produces a stable or chemically feasible compound, such as a compound that will not spontaneously transform, such as by rearrangement, cyclization, elimination, etc. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at each position. It will be understood by those skilled in the art that the substituents themselves may be substituted if appropriate. Unless specifically indicated as "unsubstituted," reference to chemical moieties herein is understood to include substituted variants. For example, reference to an "aryl" group or moiety implicitly includes both unsubstituted aryl groups and substituted variants.
[0097] Throughout this application, the “suitable substituents” mentioned above are understood to include, but are not limited to, the alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, cyano, hydroxy, amino, monoalkylamino, dialkylamino, nitro, aryl, heteroaryl, cycloalkyl (e.g., cycloalkyl, cycloalkenyl, etc.), heterocyclyl, etc. described herein; these groups as substituents, including alkyl, alkenyl, alkynyl, alkyl in haloalkyl, alkenyl in haloalkenyl, alkynyl in haloalkynyl, alkoxy, alkyl in monoalkylamino, alkyl in dialkylamino, aryl, heteroaryl, cycloalkyl and heterocyclyl themselves are also optionally substituted, for example, they may be optionally substituted with one or more groups selected from alkyl, halogen, haloalkyl, alkoxy, hydroxy, amino, monoalkylamino, dialkylamino, nitro, aryl, heteroaryl, cycloalkyl and heterocyclyl.
[0098] In some embodiments, the "suitable substituent" is selected from hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, C1-C4 alkoxycarbonyl, cyano, -S(O)2-C1-C4 alkyl optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C(O)-C1-C4 alkyl, C3-C8 cycloalkyloxy and optionally 1 , 6-14 membered aryl, 5-10 membered heteroaryl, C3-C8 cycloalkyl and 4-9 membered heterocyclyl substituted with 2 or 3 substituents selected from C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy, halo-substituted C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxyl, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, C3-C8 cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl. In some embodiments, the “suitable substituents” are hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R" and substituted or unsubstituted alkoxy, wherein R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl. In some embodiments, the “suitable substituents” are selected from deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy. In some embodiments, the “suitable substituents” are deuterium, hydroxy, methyl, F and methoxy. In some embodiments, the “suitable substituents” are selected from hydroxy, halogen, C1-C4 alkoxy, cyano and -S(O)2-C1-C4 alkyl. In some embodiments, the “suitable substituents” are hydroxyhalogen, hydroxy, cyano, -S(O)2-C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkoxy. In some embodiments, the "suitable substituent" is hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and cyano. In some embodiments, the "suitable substituent" is F, hydroxy, and cyano.
[0099] As used herein, the terms "moiety," "moiety," "chemical moiety," "group," and "chemical group" refer to specific segments or functional groups in a molecule. A chemical moiety is generally considered to be a chemical entity embedded in or attached to a molecule.
[0100] Those skilled in the art will also appreciate that in the methods described below, the intermediate compound functional groups may need to be protected by appropriate protecting groups. Such functional groups include hydroxyl, amino, amidino, guanidino, sulfhydryl and carboxyl. Suitable hydroxy protecting groups include trialkylsilyl or diarylalkylsilyl (e.g., tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, etc. Suitable protecting groups for amino, amidino and guanidino include tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable sulfhydryl protecting groups include -C (O) -R X (where R X is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl, etc. Suitable carboxyl protecting groups include alkyl esters, aryl esters or aralkyl esters.
[0101] Protecting groups can be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting groups is described in detail in Greene, TW and PGM Wuts, Protective Groups in Organi Synthesis, (1999), 4th Ed., Wiley. Protecting groups can also be polymeric resins.
[0102] As used herein, a "subject" is a mammal, such as a primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc., especially a primate, more specifically a human. In some embodiments, the "mammal" is selected from: humans; domesticated animals, such as laboratory animals, household pets or farm animals, such as cats, dogs, pigs, cows, sheep, goats, horses, rabbits; and non-domesticated animals, such as wild animals. The subject may be suspected of having prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioblastoma, melanoma, renal cell carcinoma, mantle cell lymphoma, pancreatic cancer, hepatocellular carcinoma, endometrial cancer, salivary gland cancer, or is at risk of having these diseases, or is suspected of having alopecia, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, age-related macular degeneration, or is at risk of having these diseases. Those skilled in the art are aware of diagnostic methods for various cancers such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioblastoma, melanoma, renal cell carcinoma, mantle cell lymphoma, pancreatic cancer, hepatocellular carcinoma, endometrial cancer, and salivary gland cancer, as well as diagnostic methods for hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal cord and bulbar muscular atrophy, or age-related macular degeneration, as well as clinical features of cancers such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioblastoma, melanoma, renal cell carcinoma, mantle cell lymphoma, pancreatic cancer, hepatocellular carcinoma, endometrial cancer, and salivary gland cancer, and clinical features of hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal cord and bulbar muscular atrophy, or age-related macular degeneration. In some embodiments, the subject is confirmed or diagnosed with the above-mentioned disease.
[0103] As used herein, the term "pharmaceutically acceptable" refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the pharmaceutically active ingredient (i.e., a compound of the present disclosure or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug, or metabolite thereof) and is relatively non-toxic, i.e., the substance can be administered to an individual without causing adverse biological reactions or interacting in an adverse manner with any component contained in the pharmaceutical composition. Pharmaceutically acceptable carriers or excipients include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that has been approved by, for example, the U.S. Food and Drug Administration (FDA) for use in humans or domestic animals.
[0104] The term "pharmaceutical composition" refers to a preparation containing a compound of the present invention or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof and a medium generally accepted in the art for delivering a biological (pharmacological) active compound to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier or excipient. The purpose of the pharmaceutical composition is to promote administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological (pharmacological) activity. In general, the pharmaceutical composition of the present invention contains 0.1% by weight to 99.5% by weight of the active pharmaceutical ingredient (i.e., a compound of the present invention or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof). In some embodiments, the pharmaceutical compositions of the present disclosure contain 0.5%-90% by weight, e.g., 1%, 1.5%, 2%, 5%, 10%, 15%, 20%, 25%, 30% or 50% by weight of the pharmaceutically active ingredient.
[0105] The compounds of the present disclosure may exist in a variety of different forms or derivatives, all of which are within the scope of the present disclosure. These forms or derivatives include, for example, tautomers, stereoisomers (e.g., enantiomers, diastereomers), racemic mixtures, geometric isomers, salts, prodrugs, solvates, isotopic substitutions, different crystal forms or polymorphs, and metabolites (specifically, active metabolites in this context).
[0106] In the present disclosure, the term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0107] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without the side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates; organic acid salts include, but are not limited to, formate, acetate, 2,2-dichloroacetate, trifluoroacetate, propionate, hexanoate, octanoate, decanoate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, alginate, ascorbate, salicylate, 4-aminosalicylate, and naphthalene disulfonate. These salts can be prepared by methods known in the art.
[0108] "Pharmaceutically acceptable base addition salts" refer to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. The salt derived from organic base includes but is not limited to following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0109] As used herein, the term "prodrug" refers to compounds that are metabolized (i.e., converted in vivo) into pharmacologically active compounds of the present disclosure after administration. When the compounds of the present disclosure are difficult to absorb from the gastrointestinal tract, their bioavailability can be improved by preparing them into prodrugs. Examples of prodrugs of the compounds of the present disclosure may include simple esters of compounds containing carboxyl groups (e.g., by reacting with C 1-4 esters of compounds containing hydroxyl groups (for example, by reacting with C 1-4 Monocarboxylic acid, C 3-6 esters obtained by condensation of dicarboxylic acids or their anhydrides, such as succinic anhydride or fumaric anhydride); imines of compounds containing amino groups (for example, by reacting with C 1-4 imines obtained by condensation of aldehydes or ketones); carbamates of compounds containing amino groups, such as those described by Leu et al. (J. Med. Chem., 42: 3623-3628 (1999)) and Greenwald et al. (J. Med. Chem., 42: 3657-3667 (1999)); acetals or ketal of compounds containing hydroxy groups (such as those obtained by condensation with chloromethyl methyl ether or chloromethyl ethyl ether according to methods known in the art).
[0110] As used herein, the term "solvate" refers to an aggregate comprising one or more molecules of the disclosed compounds and one or more solvent molecules. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the disclosed compounds may exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, and the like, as well as the corresponding solvated forms. The disclosed compounds may be true solvates, while in other cases, the disclosed compounds may merely retain adventitious water or a mixture of water plus some adventitious solvent.
[0111] As used herein, "stereoisomers" refer to compounds composed of the same atoms, bonded by the same bonds, but having different three-dimensional structures. The present disclosure is intended to encompass various stereoisomers and mixtures thereof.
[0112] When the compounds of the present disclosure contain olefinic double bonds, and unless specified otherwise, it is intended that the compounds of the present disclosure include both E- and Z- geometric isomers.
[0113] "Tautomer" refers to an isomer formed by a proton shift from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compounds of the present disclosure are intended to be encompassed within the scope of the present disclosure.
[0114] The compounds of the present invention or their pharmaceutically acceptable salts may contain one or more chiral carbon atoms and may therefore produce enantiomers, diastereomers and other stereoisomeric forms. Each chiral carbon atom can be defined as (R)- or (S)- based on stereochemistry. The present disclosure is intended to include all possible isomers, as well as racemates and optically pure forms thereof. The compounds of the present invention may be prepared using racemates, diastereomers or enantiomers as starting materials or intermediates. Optically active isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as crystallization and chiral chromatography.
[0115] Conventional techniques for preparing / isolating individual isomers include chiral synthesis from appropriate optically pure precursors, or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high performance liquid chromatography, see, for example, Gerard Gübitz and Martin G. Schmid (Eds.), Chiral SepaRations, Methods and Protocols, Methods in Molecular Biology, Vol. 243, 2004; A.M. Stalcup, Chiral SepaRations, Annu. Rev. Anal. Chem. 3: 341-63, 2010; Fumiss et al. (eds.), VOGEL'S ENCYCLOPEDIA OF PRaCTICAL ORGANIC CHEMISTRY. sup. TH ED., Longman Scientific and Technical Ltd., Essex, 1991, 809-816; Heller, Acc. Chem. Res. 1990, 23, 128, the disclosures of which are incorporated herein by reference in their entirety.
[0116] The present disclosure also includes all suitable isotopic substitutions (or isotopic variants) of the compounds of the present disclosure or their pharmaceutically acceptable salts. Isotopic variants of the compounds of the present disclosure or their pharmaceutically acceptable salts are defined as those in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass commonly found in nature. Isotopes that can be incorporated into the compounds of the present disclosure and their pharmaceutically acceptable salts include, but are not limited to, isotopes of H, C, N, and O, for example 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 35 S. 18 F. 36 Cl and 125 I. Isotopic variations of the compounds of the present disclosure or pharmaceutically acceptable salts thereof can be prepared by conventional techniques using appropriate isotopic variations of suitable reagents.
[0117] Herein, unless otherwise specified, the wavy line on each structural formula or group generally indicates the position where the structural formula or group is connected to other parts in the compound.
[0118] As used herein, the terms "crystal form," "crystalline form," and "polymorph" are used interchangeably and refer to crystal structures in which a compound (or a salt, solvate, or other derivative thereof, such as a prodrug or metabolite) can crystallize in different crystal packing arrangements (all having the same elemental composition). Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, crystallization rate, storage temperature, or other factors may cause one crystal form to dominate. Polymorphs of a compound can be prepared by crystallization under different conditions.
[0119] As used herein, the terms "metabolite" and "active metabolite" are used interchangeably and refer to pharmacologically active derivatives of the parent pharmaceutical active ingredient that result from metabolic processes in the subject. For example, such metabolites can result from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc. of the administered compound or salt or prodrug.
[0120] As used herein, "prevention" refers to preventing the disease or condition from occurring in a mammal (preferably a human), particularly when the mammal is susceptible to the condition but has not yet been diagnosed with the condition, or preventing the recurrence of a disease or condition that has been cured in a mammal (preferably a human).
[0121] As used herein, "treating" encompasses treatment of a disease or condition of interest in a mammal, preferably a human, suffering from the disease or condition of interest, including one or more of the following: (i) inhibiting the disease or condition, i.e., arresting its development; (ii) alleviating the disease or condition, i.e., causing regression of the disease or condition; and (iii) alleviating the symptoms caused by the disease or condition, i.e., alleviating pain without resolving the underlying disease or condition.
[0122] "Effective amount" refers to a therapeutically effective amount or a prophylactic effective amount. "Therapeutically effective amount" refers to an amount that effectively achieves the desired therapeutic outcome (alleviates one or more symptoms of the disease or condition being treated to some extent, such as reduced tumor size, increased lifespan, or increased life expectancy) at the required dose and for the required period of time. The therapeutically effective amount of a compound can be varied according to factors such as the subject's disease state, age, sex, and weight, and the ability of the compound to elicit the desired response in the subject. The dosing regimen can be adjusted to provide the optimal therapeutic response. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the compound are exceeded by the therapeutically beneficial effects. A "prophylactic effective amount" refers to an amount that effectively achieves the desired prophylactic outcome (such as preventing the occurrence of the disease in a subject at risk of the disease and the recurrence of the disease in a cured patient) at the required dose and for the required period of time. Typically, a prophylactic dose is used in a subject before or in the early stages of the disease so that the prophylactic effective amount can be less than the therapeutically effective amount. Techniques such as dose escalation trials can be used to determine the effective amount suitable for any individual case.
[0123] As used herein, the terms "administer," "administer," "dosing," and the like refer to methods that enable a compound or pharmaceutical composition to be delivered to the desired site for biological action. Methods of administration known in the art can be used in the present disclosure. These methods include, but are not limited to, oral administration, intraduodenal administration, parenteral administration (including intrapulmonary, intranasal administration; intrathecal, intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. Those skilled in the art are familiar with administration techniques that can be used for the compounds and methods described herein, such as those discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. In a preferred embodiment, the compounds of the present disclosure, their pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, isotopically substituted products, polymorphs, prodrugs or metabolites, or pharmaceutical compositions thereof, are administered orally.
[0124] As used herein, the terms "combination," "drug combination," "drug combination," or "combination therapy" refer to a medical therapy achieved by mixing or combining more than one active ingredient, and include both fixed and non-fixed combinations of active ingredients, as well as combinations of two or more different therapeutic approaches. The term "fixed combination" means that at least one compound described herein and at least one other active ingredient are administered to a patient simultaneously as a single entity or single dosage form. The term "non-fixed combination" means that at least one compound described herein and at least one other active ingredient are administered to a patient simultaneously, in combination, or sequentially at variable intervals as separate entities. This also applies to cocktail therapies, e.g., administration of three or more active ingredients.
[0125] For the avoidance of doubt, in this disclosure, compounds drawn with wedge-shaped bonds (such as compound 67) are compounds of a single configuration with a defined absolute stereochemical structure.
[0126] II.Compounds
[0127] In one aspect, the present disclosure provides a compound represented by the following Formula I, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof:
[0128] Where:
[0129] X1 is selected from: O and NR a ;
[0130] X2 is selected from: C and N;
[0131] X3 is selected from: C and N;
[0132] Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2、C(R 13 )、-OCH2-、-N(R 12 )CH2-, -CH2CH2- and N(R 12 ), and Y5 and Y6 are not bonds at the same time;
[0133] Y1 and Y4 are independently selected from the group consisting of: a bond, O, N, C, S, -S(O)-, -C(O)-, -S(O)2-, CH, CH2, NH, C(R 13 )、CH(R 13 )、C(R 13 )2 and N(R 12 ), provided that Y1 and Y4, Y1 and Y5, Y4 and Y6 are not simultaneously a bond, O, S, -S(O)- or -S(O)2- and satisfy the bond valence theory;
[0134] Alternatively, when Y1, Y4 and Y6 are arbitrarily selected from C(R 13 )2, two R on the same carbon atom 13 The C atom connected thereto may form a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered heterocyclic group, thereby forming a spiro ring structure with ring B;
[0135] Alternatively, the ring atoms in Y1 or Y6, the ring atoms in Y4, and the substituents attached to the ring atoms form a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, a substituted or unsubstituted 4-9 membered heterocyclic group, a substituted or unsubstituted 6-10 membered aryl group, or a substituted or unsubstituted 5-10 membered heteroaryl group, thereby forming a parallel ring structure with ring B;
[0136] Alternatively, X2 together with the ring atoms in Y6 and R 11 The connected ring atoms and the substituents connected to the ring atoms constitute a substituted or unsubstituted 5- or 6-membered cyclic hydrocarbon group, a substituted or unsubstituted 5- or 6-membered heterocyclic group, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- or 6-membered heteroaryl group, thereby forming a tricyclic structure with rings A and B;
[0137] Ring B is a 5-, 6- or 7-membered heterocyclic ring, a benzene ring or a 5-, 6- or 7-membered heteroaromatic ring; Ring B may optionally be replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R" and substituted or unsubstituted alkoxy;
[0138] R1 is selected from: cyano and -C(O)NR'R";
[0139] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0140] R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic;
[0141] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0142] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;
[0143] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; each of the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from N and O;
[0144] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0145] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0146] R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen;
[0147] R 10 is selected from: H, halogen, and substituted or unsubstituted alkyl;
[0148] R 11 is selected from the group consisting of: H, hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R", and substituted or unsubstituted alkoxy;
[0149] Each R not participating in the ring 12 independently selected from the group consisting of: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-14 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl;
[0150] Each R not participating in the ring 13 independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C6-14 aryl-S(O)2-, substituted or unsubstituted 3-6 membered cyclic hydrocarbon group-C(O)- and NR'R"-C(O)-, or two R on the same carbon atom 13 Forming oxo (=O) or thio (=S);
[0151] R 13 or R12 After participating in the ring formation, its ring atoms may be optionally substituted by 1-3 heteroatoms selected from O, N and S;
[0152] R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl;
[0153] R a Selected from H and C1-C4 alkyl;
[0154] Here, the dotted line indicates the presence or absence of a double bond.
[0155] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, C1-C4 alkyl-S(O)2-, and halo-C1-C4 alkyl.
[0156] In some embodiments, the compound of Formula I has the structure shown in Formula Ia below:
[0157] In some embodiments, the compound of Formula I has the structure shown in Formula Ib below:
[0158] Where,
[0159] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0160] In some embodiments, Ring A is a benzene ring or a 6-membered heteroaryl ring.
[0161] In some embodiments, Ring A is a benzene ring or a pyridine ring.
[0162] In some embodiments, the compound of formula I has the structure shown in the following formula IIa:
[0163] Where,
[0164] Y4 is selected from the group consisting of: C, CH and N;
[0165] Y6 is selected from the group consisting of: C, CH, and N;
[0166] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0167] R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0168] n is 0, 1, 2, 3 or 4.
[0169] In some embodiments, X2 is selected from: C and N;
[0170] X3 is selected from: C and N;
[0171] Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0172] Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-;
[0173] Y4 is selected from: C, CH or N;
[0174] Y6 is selected from: C, CH or N;
[0175] R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl;
[0176] n is 0 or 1;
[0177] R1 is selected from: cyano and -C(O)NR'R";
[0178] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0179] R3 is selected from: substituted or unsubstituted aryl;
[0180] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atoms to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0181] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0182] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0183] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0184] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0185] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0186] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0187] R' and R" are each independently selected from H and C1-C4 alkyl;
[0188] Here, the dotted line indicates the presence or absence of a double bond.
[0189] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0190] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3; R2 is selected from the group consisting of: H, fluoro, and methoxy;
[0191] R3 is phenyl;
[0192] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0193] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0194] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0195] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0196] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0197] The wavy lines indicate the bond connection locations;
[0198] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0199] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0200] R 10 Selected from: H, F and methyl;
[0201] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0202] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3, and
[0203] In some embodiments, the compound of Formula I has the structure shown in the following Formula IIb:
[0204] Where,
[0205] Y1 is selected from the group consisting of: C, CH and N;
[0206] Y4 is selected from the group consisting of: C, CH and N;
[0207] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0208] R 15Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0209] n is 0, 1, 2, 3 or 4.
[0210] In some embodiments, X2 and X3 are C;
[0211] Y1 is selected from the group consisting of: C, CH and N;
[0212] Y4 is selected from the group consisting of: C, CH and N;
[0213] Y5 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, NH, -N(CH3)-, CH2, -CH(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-;
[0214] Y6 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, CH2, CH, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; and Y5 and Y6 are not simultaneously a bond;
[0215] R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl;
[0216] n is 0 or 1;
[0217] R1 is selected from: cyano and -C(O)NR'R";
[0218] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0219] R3 is selected from: substituted or unsubstituted aryl;
[0220] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0221] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0222] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0223] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0224] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0225] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0226] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0227] R' and R" are each independently selected from H and C1-C4 alkyl;
[0228] Here, the dotted line indicates the presence or absence of a double bond.
[0229] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3;
[0230] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0231] R3 is phenyl;
[0232] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0233] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0234] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0235] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0236] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0237] The wavy lines indicate the bond connection locations;
[0238] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0239] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0240] R 10 Selected from: H, F and methyl;
[0241] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0242] In some embodiments, ring D is a 3-6 membered cycloalkyl, a 4-6 membered heterocyclyl, a 6-10 membered aryl, or a 5-8 membered heteroaryl, wherein the 4-6 membered heterocyclyl and the 5-8 membered heteroaryl contain 1, 2, or 3 heteroatoms selected from O, N, and S; R 15 Selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0, 1 or 2.
[0243] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3, and In some embodiments, R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1.
[0244] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0245] In some embodiments, the compound of Formula I has the structure shown in the following Formula IIc:
[0246] Where,
[0247] Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S;
[0248] R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0249] n is 0, 1, 2, 3 or 4.
[0250] In some embodiments, X2 and X3 are C;
[0251] Y1 is selected from: O or CH2;
[0252] Y5 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0253] Y6 is selected from the group consisting of: a bond, O, S, N, CH2, CH, NH, and -N(CH3)-;
[0254] R 16 is selected from halogen, C1-C4 alkyl, hydroxy, C1-C4 acyl and C1-C4 alkoxy;
[0255] R1 is selected from: cyano and -C(O)NR'R";
[0256] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0257] R3 is selected from: substituted or unsubstituted aryl;
[0258] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0259] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0260] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0261] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0262] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0263] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0264] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0265] R' and R" are each independently selected from H and C1-C4 alkyl;
[0266] Here, the dotted line indicates the presence or absence of a double bond.
[0267] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3;
[0268] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0269] R3 is phenyl;
[0270] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0271] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0272] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0273] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0274] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0275] The wavy lines indicate the bond connection locations;
[0276] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0277] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0278] R 10 Selected from: H, F and methyl;
[0279] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0280] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0281] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3, and
[0282] In some embodiments, the compound of Formula I has the structure shown in the following Formula IId:
[0283] Where,
[0284] Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S;
[0285] R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0286] n is 0, 1, 2, 3 or 4.
[0287] In some embodiments, X2 and X3 are C;
[0288] Y4 is selected from: O or CH2;
[0289] Y5 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0290] Y6 is selected from the group consisting of: a bond, O, S, N, CH2, CH, NH, and -N(CH3)-;
[0291] R 16 is selected from halogen, C1-C4 alkyl, hydroxy, C1-C4 acyl and C1-C4 alkoxy;
[0292] R1 is selected from: cyano and -C(O)NR'R";
[0293] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0294] R3 is selected from: substituted or unsubstituted aryl;
[0295] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0296] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0297] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0298] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0299] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0300] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0301] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0302] R' and R" are each independently selected from H and C1-C4 alkyl;
[0303] Here, the dotted line indicates the presence or absence of a double bond.
[0304] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3;
[0305] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0306] R3 is phenyl;
[0307] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0308] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0309] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0310] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0311] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0312] The wavy lines indicate the bond connection locations;
[0313] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0314] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0315] R 10 Selected from: H, F and methyl;
[0316] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0317] In some embodiments, Ring E is a 3-6 membered cycloalkyl or a 4-6 membered heterocyclyl, wherein the 4-6 membered heterocyclyl contains 1, 2 or 3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, C1-C4 alkyl, hydroxyl and acetyl; n is 0 or 1.
[0318] In some embodiments, Ring E is cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl, oxetanyl, oxolanyl, tetrahydropyranyl, azetidinyl, azolidinyl, or piperidinyl; R 16 is selected from H, fluorine, methyl, ethyl, hydroxyl and acetyl; n is 0 or 1.
[0319] In some embodiments, the compound of Formula I has the structure shown in Formula IIe below:
[0320] Where,
[0321] X2 is C;
[0322] Y6 is selected from the group consisting of: C, CH, and N;
[0323] Ring F is a 5- or 6-membered cycloalkyl, a 5- or 6-membered heterocyclyl, a phenyl group, or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heterocyclyl group or the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S;
[0324] R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl -C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; and
[0325] n is 0, 1, 2 or 3.
[0326] In some embodiments, ring F is phenyl or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S; and / or R 15Selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl. In some embodiments, the C1-C4 acyl, C1-C4 alkoxy, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl, and n is 0, 1 or 2.
[0327] In some embodiments, Ring F is a 5-membered heteroaryl group, wherein the 5-membered heteroaryl group contains 1 or 2 heteroatoms selected from O and N; and / or R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; wherein R' and R" are each independently selected from H and C1-C4 alkyl. In some embodiments, n is 0 or 1.
[0328] In some embodiments, Ring F is pyrrolyl, furanyl, pyrazolyl, imidazolyl, oxazolyl, or isoxazolyl.
[0329] In some embodiments, Y1, Y4 and Y5 are independently selected from: O, CH, CH2, -CH(CH3)-, N, NH and -N(CH3)-;
[0330] Ring F is phenyl or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heteroaryl group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1;
[0331] R1 is selected from: cyano and -C(O)NR'R";
[0332] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0333] R3 is selected from: substituted or unsubstituted aryl;
[0334] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0335] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0336] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0337] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0338] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0339] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0340] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0341] R' and R" are each independently selected from H and C1-C4 alkyl;
[0342] Here, the dotted line indicates the presence or absence of a double bond.
[0343] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3;
[0344] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0345] R3 is phenyl;
[0346] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0347] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0348] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0349] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0350] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0351] The wavy lines indicate the bond connection locations;
[0352] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0353] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0354] R 10 Selected from: H, F and methyl;
[0355] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0356] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0357] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3, and
[0358] In some embodiments, the compound of formula IIa has the structure shown in formula IIIa below:
[0359] Where,
[0360] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ;
[0361] D2 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0362] D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CRf ) p and (CR f R g ) p ;
[0363] The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory;
[0364] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0365] Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0366] Each R gis independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0367] Or R on the same carbon atom f and R g forming an oxo (=O) or thio (=S) group; and
[0368] Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
[0369] In some embodiments, X2 is selected from: C and N;
[0370] X3 is selected from: C and N;
[0371] Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0372] Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-;
[0373] Y4 is selected from: C, CH or N;
[0374] Y6 is selected from: C, CH or N;
[0375] D1 is selected from: O, S, N, NR e , CR f and CR f R g ;
[0376] D2 is selected from: O, S, N, NR e 、(CR f ) p and (CR f R g ) p ;
[0377] D3 is selected from: O, S, N, NR e 、(CR f )p and (CR f R g ) p ;
[0378] R1 is selected from: cyano and -C(O)NR'R";
[0379] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0380] R3 is selected from: substituted or unsubstituted aryl;
[0381] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0382] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0383] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0384] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0385] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0386] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0387] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0388] R' and R" are each independently selected from H and C1-C4 alkyl;
[0389] Here, the dotted line indicates the presence or absence of a double bond.
[0390] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3;
[0391] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0392] R3 is phenyl;
[0393] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0394] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0395] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0396] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0397] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0398] The wavy lines indicate the bond connection locations;
[0399] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0400] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0401] R 10 Selected from: H, F and methyl;
[0402] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0403] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3, and
[0404] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0405] In some embodiments, the compound of formula IIb has the structure shown in formula IIIb below:
[0406] Where,
[0407] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ;
[0408] D2 is selected from: O, S, S(O), S(O)2, N, NR e 、(CRf ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0409] D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ;
[0410] The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory;
[0411] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0412] Each R fis independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0413] Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0414] Or R on the same carbon atom f and R g forming an oxo (=O) or thio (=S) group; and
[0415] Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
[0416] In some embodiments, X2 and X3 are C;
[0417] Y1 is selected from the group consisting of: C, CH and N;
[0418] Y4 is selected from the group consisting of: C, CH and N;
[0419] Y5 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, NH, -N(CH3)-, CH, CH2, -CH(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-;
[0420] Y6 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, CH2, CH, -CH(CH3)-, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; and Y5 and Y6 are not simultaneously a bond;
[0421] D1 is selected from: O, S, N, NR e , CR f and CR f R g ;
[0422] D2 is selected from: O, S, N, NR e 、(CR f ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0423] D3 is selected from: O, S, N, NR e 、(CR f ) p and (CR f R g ) p ;
[0424] R1 is selected from: cyano and -C(O)NR'R";
[0425] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0426] R3 is selected from: substituted or unsubstituted aryl;
[0427] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0428] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0429] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxyl, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0430] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0431] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0432] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0433] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0434] R' and R" are each independently selected from H and C1-C4 alkyl;
[0435] Here, the dotted line indicates the presence or absence of a double bond.
[0436] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, and -C(O)NHCH3;
[0437] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0438] R3 is phenyl;
[0439] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0440] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0441] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, wherein the substituents are 1, 2 or 3 selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, wherein the C1-C4 alkyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein the R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; or
[0442] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0443] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0444] The wavy lines indicate the bond connection locations;
[0445] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0446] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0447] R 10 Selected from: H, F and methyl;
[0448] R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0449] In some embodiments, R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3, and
[0450] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0451] In some embodiments, the compound of formula IIIa has the structure shown in formula IVa below:
[0452] Where,
[0453] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0454] In some embodiments, the compound of formula IIIb has the structure shown in formula IVb below:
[0455] Where,
[0456] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0457] In some embodiments, the compound of formula IIe has the structure shown in formula IVc below:
[0458] Where,
[0459] Y7, Y8 and Y9 are independently selected from: a bond, O, S, S(O), S(O)2, N, NR e , CR f and CR f R g , provided that at most one of Y7, Y8 and Y9 is a bond, Y7 and Y8, Y8 and Y9 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory,
[0460] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0461] Each R fis independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0462] Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0463] Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S);
[0464] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0465] In some embodiments, ring C is a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclyl, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclyl, or a substituted or unsubstituted 6-12 membered nitrogen-containing heterocyclyl, each of which optionally further contains 1 or 2 heteroatoms selected from N and O.
[0466] In some embodiments, Ring C is a 4-9 membered monocyclic or cyclic heterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy.
[0467] In some embodiments, Ring C is optionally substituted with 1, 2, or 3 substituents selected from H, deuterium, hydroxy, methyl, F, and methoxy:
[0468] The wavy lines indicate the locations of key connections.
[0469] In some embodiments, Ring C is optionally substituted with 1, 2, or 3 substituents selected from H, deuterium, hydroxy, methyl, F, and methoxy.
[0470] In some embodiments, R1 is selected from the group consisting of: cyano and -C(=O)NR'R"; said R' and R" are each independently selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkyl-S(O)2- and halo-C1-C4 alkyl.
[0471] In some embodiments, R1 is selected from: cyano and -C(=O)NR'R"; said R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halo-C1-C4 alkyl.
[0472] In some embodiments, R1 is selected from the group consisting of: cyano, -C(=O)NH2, and -C(=O)NHCH3.
[0473] In some embodiments, R1 is selected from the group consisting of: cyano, -C(=O)NH2, -C(=O)NHCH3, and
[0474] In some embodiments, R1 is -C(O)NR'R".
[0475] In some embodiments, R1 is -C(O)NHR'; wherein R' is selected from H and C1-C4 alkyl.
[0476] In some embodiments, R1 is -C(O)NHR'; wherein R' is selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0477] In some embodiments, R1 is -C(O)NH2.
[0478] In some embodiments, R1 is -C(O)NHCH3.
[0479] In some embodiments, R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl, and substituted or unsubstituted C1-C4 alkoxy.
[0480] In some embodiments, R2 is selected from H, halogen, C1-C4 alkyl, and C1-C4 alkoxy.
[0481] In some embodiments, R2 is selected from H, halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0482] In some embodiments, R2 is selected from H, halogen, and methoxy.
[0483] In some embodiments, R2 is halogen.
[0484] In some embodiments, R2 is selected from fluoro and chloro.
[0485] In some embodiments, R2 is fluoro.
[0486] In some embodiments, R3 is selected from phenyl or heteroaryl, which is unsubstituted or substituted with 1-3 substituents selected from hydroxy, halogen, C1-C4 alkyl, halo-substituted C1-C4 alkyl, and C1-C4 alkoxy.
[0487] In some embodiments, R3 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
[0488] In some embodiments, R3 is selected from substituted or unsubstituted phenyl and substituted or unsubstituted pyridinyl.
[0489] In some embodiments, R3 is phenyl, fluorophenyl, or pyridyl.
[0490] In some embodiments, R3 is phenyl.
[0491] In some embodiments, R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, which optionally contains 1, 2 or 3 heteroatoms selected from O, N and S.
[0492] In some embodiments, R4 and R5 are each independently selected from: H and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, which optionally contains 1, 2 or 3 heteroatoms selected from O, N and S.
[0493] In some embodiments, R4 and R5 are each independently selected from: H, substituted or unsubstituted C1-C3 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, which optionally contains 1, 2 or 3 heteroatoms selected from O, N and S.
[0494] In some embodiments, R4 and R5 are each independently selected from the group consisting of: H and substituted or unsubstituted C1-C4 alkyl.
[0495] In some embodiments, R4 and R5 are each independently selected from the group consisting of: H and substituted or unsubstituted C1-C3 alkyl.
[0496] In some embodiments, R4 and R5 are each independently selected from the group consisting of: H and C1-C3 alkyl.
[0497] In some embodiments, R4 and R5 are each independently selected from: H and methyl.
[0498] In some embodiments, R4 and R5 are both H.
[0499] In some embodiments, R6 is selected from: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl, substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclyl, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclyl, substituted or unsubstituted 6-12 membered spirocyclyl and substituted or unsubstituted 6-12 membered spiroheterocyclyl.
[0500] In some embodiments, R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, -S(O)2-C1-C4 alkyl optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR '-C(O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0501] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0502] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from: C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxyl, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl.
[0503] In some embodiments, R6 is selected from: H; C1-C4 alkyl, which is optionally substituted with 1, 2 or 3 substituents selected from hydroxy, halogen, C1-C4 alkoxy, cyano and C1-C4 alkyl-S(O)2-; 3-8 membered cyclic hydrocarbon group, which is optionally substituted with 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, C1-C4 alkyl-S(O)2-, C1-C4 alkyl and C1-C4 alkoxy; 4- a 9-membered heterocyclic group, which is optionally substituted by 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, C1-C4 alkyl-S(O)2-, C1-C4 alkyl and C1-C4 alkoxy; and a 6-12-membered bridged cyclic group, a 6-12-membered spirocyclic group, a 6-12-membered bridged heterocyclic group or a 6-12-membered spiroheterocyclic group, each of which is optionally substituted by 1, 2 or 3 substituents selected from C1-C4 alkyl, C1-C4 alkoxy and cyano.
[0504] In some embodiments, R6 is -LWZ, wherein L is a bond or a substituted or unsubstituted C1-C4 alkyl group; W is a bond, a substituted or unsubstituted C1-C4 alkyl group, a substituted or unsubstituted 3-8 membered cycloalkyl group, a substituted or unsubstituted 6-14 membered aryl group, a substituted or unsubstituted 5-10 membered heteroaryl group, a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged ring group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, a substituted or unsubstituted a 6-12 membered spirocyclic group or a substituted or unsubstituted 6-12 membered spiroheterocyclic group; Z is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl, -S(O)2-C1-C4 alkyl, -S(O)2-NR'R", -S(O)2-NH2, cyano, -C(O)-C1-C4 alkyl, -O-3-8 membered cycloalkyl or -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently H or C1-C4 alkyl.
[0505] In some embodiments, the -LWZ is selected from:
[0506] , where the wavy lines indicate the locations of bond connections.
[0507] In some embodiments, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group, or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2, or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen, and C1-C4 alkoxy.
[0508] In some embodiments, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0509] The wavy lines indicate the locations of key connections.
[0510] In some embodiments, R4 or R5 together with R6 and the atoms to which they are attached form a radical optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy.
[0511] In some embodiments, R7 and R8 are each independently selected from the group consisting of H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C2-C4 alkenyl, and substituted or unsubstituted C2-C4 alkynyl.
[0512] In some embodiments, R7 and R8 are each independently selected from the group consisting of H, halogen, cyano, substituted or unsubstituted C1-C3 alkyl, substituted or unsubstituted C1-C3 haloalkyl, substituted or unsubstituted C1-C3 alkoxy, substituted or unsubstituted C2-C4 alkenyl, and substituted or unsubstituted C2-C4 alkynyl.
[0513] In some embodiments, R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, methyl, and methoxy.
[0514] In some embodiments, R7 and R8 are each independently selected from the group consisting of: fluoro and chloro.
[0515] In some embodiments, R7 is chloro and R8 is fluoro.
[0516] In some embodiments, R9 is selected from H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl, and halogen.
[0517] In some embodiments, R9 is selected from H, C1-C3 alkyl, C1-C3 alkoxy, hydroxyl, and halogen.
[0518] In some embodiments, R9 is selected from H, methyl, methoxy, hydroxy, and F.
[0519] In some embodiments, R9 is H.
[0520] In some embodiments, R 10 Selected from: H, halogen and C1-C4 alkyl.
[0521] In some embodiments, R 10 Selected from: H, halogen and C1-C3 alkyl.
[0522] In some embodiments, R 10 Selected from: H, F and methyl.
[0523] In some embodiments, R 10 For H.
[0524] In some embodiments, R 11 Selected from: H, hydroxy, amino, halogen, C1-C3 alkyl, -NR'R" and C1-C3 alkoxy, wherein R' and R" are independently selected from C1-C4 alkyl.
[0525] In some embodiments, R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0526] In some embodiments, R 11 For H.
[0527] In some embodiments, when R not participating in the ring formation 12 When present, they are each independently selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl-C(O)- and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
[0528] In some embodiments, when R not participating in the ring formation 12 When present, they are each independently selected from: H, acetyl, propionyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-6 membered heterocyclyl, 3-5 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkyl is optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
[0529] In some embodiments, when R not participating in the ring formation 13 When present, they are each independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cyclic hydrocarbon group-C(O)- and NR'R"-C(O)-, or two R on the same carbon atom 13To form an oxo (=O) or thioxo (=S); wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C6 alkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cyclic hydrocarbon group-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
[0530] In some embodiments, when R not participating in the ring formation 13 When present, they are each independently selected from: H, fluorine, chlorine, C1-C4 acyl, hydroxy, cyano, C1-C4 alkoxy, C1-C6 alkyl, C1-C4 alkyl-S(O)2- and 3-4 membered cycloalkyl-C(O)-.
[0531] In some embodiments, R' and R" are each independently selected from H and C1-C4 alkyl.
[0532] In some embodiments, R' and R" are each independently selected from H, methyl, and ethyl.
[0533] In some embodiments, R a Selected from H, methyl and ethyl.
[0534] In some embodiments, R 14 is H, halogen or C1-C4 alkyl.
[0535] In some embodiments, R 14 is H or methyl.
[0536] In some embodiments, R 14 For H.
[0537] In some embodiments, R 15 Selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxyl, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; R' and R" are each independently selected from H and C1-C4 alkyl.
[0538] In some embodiments, R 15Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl.
[0539] In some embodiments, R 16 Selected from halogen, C1-C4 alkyl, hydroxy, C1-C4 acyl and C1-C4 alkoxy.
[0540] In some embodiments, R 16 Selected from H, halogen, C1-C4 alkyl, hydroxyl and acetyl.
[0541] In some embodiments, R 16 Selected from H, hydroxy, halogen and C1-C4 alkyl.
[0542] In some embodiments, R 16 Selected from H, fluorine, methyl, ethyl, hydroxyl and acetyl.
[0543] In some embodiments, R 16 is H, hydroxyl or methyl.
[0544] In some embodiments, R 16 For H.
[0545] In some embodiments, n is 0, 1, 2, 3, or 4.
[0546] In some embodiments, n is 0, 1, or 2.
[0547] In some embodiments, n is 0 or 1.
[0548] In some embodiments, X1 is O.
[0549] In some embodiments, X1 is NH.
[0550] In some embodiments, X1 is N(CH3).
[0551] In some embodiments, X2 is C.
[0552] In some embodiments, X2 is N.
[0553] In some embodiments, X3 is C.
[0554] In some embodiments, X3 is N.
[0555] In some embodiments, Y5 is selected from the group consisting of: O, S, N, CH(R 13 )、C(R 13)、-OCH2-、-N(R 12 )CH2-, -CH2CH2- or N(R 12 ).
[0556] In some embodiments, Y5 is selected from the group consisting of: a bond, O, S, -S(O)-, N, CH2, CH, -C(O)-, -CH(OH)-, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-.
[0557] In some embodiments, Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH, and -N(CH3)-.
[0558] In some embodiments, Y5 is selected from the group consisting of: a bond, O, S, N, CH2, CH, NH, and -N(CH3)-.
[0559] In some embodiments, Y5 is selected from the group consisting of: a bond, O, CH2, NH, -N(CH3)-, and -CH(CH3)-.
[0560] In some embodiments, Y5 is O.
[0561] In some embodiments, Y5 is CH or CH2.
[0562] In some embodiments, Y5 is NH or N.
[0563] In some embodiments, Y6 is selected from: O, N, -S(O)-, -SO2-, S, CH(R 13 )、C(R 13 )、-OCH2-、-N(R 12 )CH2-, -CH2CH2- and N(R 12 ).
[0564] In some embodiments, Y6 is selected from: a bond, O, S, -S(O)-, -S(O)2-, N, CH, -C(O)-, CH2, NH, -N(CH3)-, -N(C2H4OH)-, -N(C(O)CH3)-, -N(C(O)C2H5)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-.
[0565] In some embodiments, Y6 is selected from the group consisting of: O, S, N, CH2, CH, NH, and -N(CH3)-.
[0566] In some embodiments, Y6 is selected from the group consisting of: a bond, O, S, N, CH, CH2, NH, and -N(CH3)-.
[0567] In some embodiments, Y1 and Y4 are independently selected from the group consisting of a bond, O, N, NH, -N(CH3)-, CH, CH2, and -CH(CH3)-, and Y1 and Y4 are not a bond or O at the same time.
[0568] In some embodiments, Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-.
[0569] In some embodiments, Y1 is selected from: O or CH2.
[0570] In some embodiments,
[0571] Y1 is selected from the group consisting of: a bond, O, N, CH, CH2, NH, CH(R 13 )、C(R 13 )2 and N(R 12 );
[0572] Y4 is selected from the group consisting of: a bond, O, N, CH, CH2, NH, CH(R 13 )、C(R 13 )2 and N(R 12 );
[0573] Furthermore, Y1 and Y4 are not a bond or O at the same time.
[0574] In some embodiments,
[0575] Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0576] Y4 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0577] Furthermore, Y1 and Y4 are not a bond or O at the same time.
[0578] In some embodiments,
[0579] Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH and -N(CH3)-;
[0580] Y6 is selected from the group consisting of: O, S, N, CH2, CH, NH and -N(CH3)-;
[0581] Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0582] Y4 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0583] Furthermore, Y1 and Y4 are not both a bond or O.
[0584] In some embodiments,
[0585] Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0586] Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH and -N(CH3)-;
[0587] And Y1 and Y5 are not 0 at the same time.
[0588] In some embodiments, Ring B may be optionally replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy.
[0589] In some embodiments, Ring B may be optionally replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted C1-C3 alkyl, -NR'R" and substituted or unsubstituted C1-C3 alkoxy.
[0590] In some embodiments, the ring A and the ring B and their substituents together form any of the following groups:
[0591] Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 11 is H, hydroxy, -NR'R", halogen or C1-C4 alkyl; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f Selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl; the wavy line indicates the position of the bond connection.
[0592] In some embodiments, R1 is cyano, -C(O)NH2, -C(O)NHCH3, and R2 is H or F; R 11 H; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, acetyl, propionyl and cyclopropionyl; f Selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, methyl, ethyl, cyclopropyl and cyclobutyl.
[0593] In some embodiments, R1 is cyano, -C(O)NH2, or -C(O)NHCH3; R2 is H or F; R 11 H; R e R is selected from H, methyl, ethyl, cyclopropyl, cyclobutyl, -CH2CH2OH, acetyl, propionyl and cyclopropionyl; f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, methyl, ethyl, cyclopropyl and cyclobutyl.
[0594] In some embodiments, R1 is -C(O)NH2 or -C(O)NHCH3; R2 is F; R 11 H; R e is selected from H, methyl, cyclopropyl and acetyl; R f Selected from H, F, Cl, hydroxy, cyano, -NH2, -CH2OH, methoxy and methyl.
[0595] In some embodiments, R1 is -C(O)NH2 or -C(O)NHCH3; R2 is F; R 11 H; R e is selected from H, methyl, cyclopropyl and acetyl; R f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy and methyl.
[0596] In some embodiments, the ring A and the ring B and their substituents together form any of the following groups:
[0597] Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 11 is H, hydroxy, -NR'R", halogen or C1-C4 alkyl; R 14 is H, halogen or C1-C4 alkyl; n is 0, 1 or 2; R 16 is selected from H, hydroxy, halogen and C1-C4 alkyl; R eR is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f Selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl; the wavy line indicates the position of the bond connection.
[0598] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0599] In some embodiments, R1 is cyano, -C(O)NH2, -C(O)NHCH3, and R2 is H or F; R 11 H; R 14 is H or methyl; n is 0, 1 or 2; R 16 is H, hydroxyl or methyl; R e R is selected from the group consisting of H, methyl, deuterated methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, acetyl, propionyl, and cyclopropionyl; f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, methyl, ethyl, cyclopropyl and cyclobutyl.
[0600] In some embodiments, R1 is cyano, -C(O)NH2, or -C(O)NHCH3; R2 is H or F; R 11 H; R 14 is H or methyl; n is 0, 1 or 2; R 16 is H, hydroxyl or methyl; R e R is selected from H, methyl, ethyl, cyclopropyl, cyclobutyl, -CH2CH2OH, acetyl, propionyl and cyclopropionyl; f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, methyl, ethyl, cyclopropyl and cyclobutyl.
[0601] In some embodiments, R1 is -C(O)NH2, -C(O)NHCH3 and R2 is F; R 11 H; R14 H; R 16 H; R e is selected from H, methyl, deuterated methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, cyclopropyl and acetyl; R f Selected from H, F, Cl, hydroxy, cyano, -NH2, -CH2OH, methoxy and methyl.
[0602] In some embodiments, R1 is -C(O)NH2 or -C(O)NHCH3; R2 is F; R 11 H; R 14 H; R 16 H; R e is selected from H, methyl, ethyl, cyclopropyl and acetyl; R f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy and methyl.
[0603] In some embodiments, the ring A and the ring B and their substituents together form any of the following groups:
[0604] Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 14 is H, halogen or C1-C4 alkyl; n is 0, 1 or 2; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f Selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl; the wavy line indicates the position of the bond connection.
[0605] In some embodiments, R1 is cyano, -C(O)NH2, -C(O)NHCH3, and R2 is H or F; R 14 is H or methyl; n is 0, 1 or 2; R eR is selected from the group consisting of H, methyl, deuterated methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, acetyl, propionyl, and cyclopropionyl; f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, methyl, ethyl, -CH2OH, cyclopropyl and cyclobutyl.
[0606] In some embodiments, R1 is cyano, -C(O)NH2, or -C(O)NHCH3; R2 is H or F; R 14 is H or methyl; n is 0, 1 or 2; R e R is selected from H, methyl, cyclopropyl, cyclobutyl, -CH2CH2OH, acetyl, propionyl and cyclopropionyl; f is selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, methyl, ethyl, cyclopropyl and cyclobutyl.
[0607] In some embodiments, X2 is selected from: C and N;
[0608] X3 is selected from: C and N;
[0609] Y5 and Y6 are independently selected from the group consisting of: O, S, N, -S(O)-, -S(O)2-, CH(R 13 )、C(R 13 )2、C(R 13 )、-OCH2-、-N(R 12 )CH2-, -CH2CH2- and N(R 12 ); and Y5 and Y6 are not bonds at the same time;
[0610] Y1 is selected from the group consisting of: a bond, O, N, CH, CH2, NH, CH(R 13 )、C(R 13 )2 and N(R 12 );
[0611] Y4 is selected from the group consisting of: a bond, O, N, CH, CH2, NH, CH(R 13 )、C(R 13 )2 and N(R 12 );
[0612] Ring B may optionally be replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy;
[0613] R1 is selected from: cyano and -C(O)NR'R";
[0614] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0615] R3 is selected from: substituted or unsubstituted aryl;
[0616] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0617] R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group;
[0618] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy;
[0619] R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy;
[0620] R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen;
[0621] R 10 Selected from: H, halogen and C1-C4 alkyl;
[0622] R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy;
[0623] Each R not participating in the ring 12independently selected from H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; said C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0624] Each R not participating in the ring 13 independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-; said C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano, or two R on the same carbon atom are 13 Forming oxo (=O) or thio (=S);
[0625] R' and R" are each independently selected from H and C1-C4 alkyl;
[0626] Here, the dotted line indicates the presence or absence of a double bond.
[0627] In some embodiments, R' and R" may also be each independently selected from C3-C6 cycloalkyl.
[0628] In some embodiments, R1 is
[0629] In some embodiments, X2 is selected from: C and N;
[0630] X3 is selected from: C and N;
[0631] Y5 is selected from the group consisting of: O, S, -S(O)-, -S(O)2-, N, CH2, CH, -C(O)-, NH, and -N(CH3)-;
[0632] Y6 is selected from the group consisting of: O, S, -S(O)-, -S(O)2-, N, CH2, CH, -C(O)-, NH and -N(CH3)-;
[0633] Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0634] Y4 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-;
[0635] H on ring B may be further optionally substituted with 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy;
[0636] R1 is selected from the group consisting of: cyano, -C(O)NH2 and -C(O)NHCH3;
[0637] R2 is selected from the group consisting of: H, fluoro and methoxy;
[0638] R3 is phenyl;
[0639] R4 and R5 are each independently selected from: H and C1-C4 alkyl;
[0640] R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[0641] R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or
[0642] R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxyl, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl;
[0643] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0644] The wavy lines indicate the bond connection locations;
[0645] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0646] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0647] R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
[0648] In some embodiments, Ring A and Ring B and their ring substituents together form any of the following groups:
[0649] Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 11is H, hydroxy, -NR'R", halogen or C1-C4 alkyl; R 14 is H, halogen or C1-C4 alkyl; n is 0, 1 or 2; R 16 is selected from H, hydroxy, halogen and C1-C4 alkyl; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f is selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl; the wavy line indicates the position of the bond attachment;
[0650] X1 is 0;
[0651] R3 is selected from phenyl which is unsubstituted or substituted with 1, 2 or 3 substituents selected from hydroxy, halogen, C1-C4 alkyl, halo-C1-C4 alkyl and C1-C4 alkoxy;
[0652] R4 is selected from H and C1-C4 alkyl;
[0653] R5 is selected from H and C1-C4 alkyl;
[0654] R6 is selected from: H; C1-C4 alkyl, which is optionally substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, C1-C4 alkoxy, cyano and -S(O)2-C1-C4 alkyl; 3-8 membered cyclic hydrocarbon group, which is optionally substituted by 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, -S(O)2-C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkoxy; 4-9 membered monocyclic or cyclic Heterocyclyl, which is optionally substituted with 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, -S(O)2-C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkoxy; and 6-12 membered bridged cyclyl, 6-12 membered spirocyclyl, 6-12 membered bridged heterocyclyl or 6-12 membered spiroheterocyclyl, each of which is optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, C1-C4 alkoxy and cyano;
[0655] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy:
[0656] The wavy lines indicate the bond connection locations;
[0657] R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy;
[0658] R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F;
[0659] R 10 Selected from: H, F and methyl.
[0660] In some embodiments, R' and R" are each independently selected from H, C1-C4 alkyl, and C3-C6 cycloalkyl.
[0661] In some embodiments, Ring A and Ring B and their ring substituents together form any of the following groups:
[0662] Wherein, R1 is -C(O)NR'R"; R2 is F; R 11 is H, F or methyl; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2(CH3)OH, -CH2CH2OCH3 and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NR'R", methoxy, ethoxy, -CH2OH, -CH2CH2OH, -CH2CH2OCH3, C1-C6 alkyl and 3-6 membered cycloalkyl, wherein R' and R" are each independently selected from H and methyl; the wavy line indicates the position of bond attachment. In some embodiments, R' and R" are each independently cyclopropyl.
[0663] In some embodiments, R1 is -C(O)NR'R"; R2 is F; R 11 is H, F or methyl; R e R is selected from H, methyl, ethyl, cyclopropyl, cyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NR'R", methoxy, ethoxy, C1-C6 alkyl and 3-6 membered cyclic hydrocarbon groups, wherein R' and R" are each independently selected from H and methyl.
[0664] In some embodiments, Ring A and Ring B and their ring substituents together form any of the following groups:
[0665] Wherein, R1 is -C(O)NR'R"; R2 is F; R 11 is H, F or methyl; R 14 is H, F or methyl; n is 0, 1 or 2; R 16 is selected from H, hydroxyl and methyl; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NR'R", methoxy, ethoxy, -CH2OH, C1-C6 alkyl and 3-6 membered cycloalkyl, wherein R' and R" are each independently selected from H and methyl; the wavy line indicates the position of bond attachment. In some embodiments, R' and R" are each independently cyclopropyl.
[0666] In some embodiments, R1 is -C(O)NR'R"; R2 is F; R 11 is H, F or methyl; R 14 is H, F or methyl; n is 0, 1 or 2; R 16 is selected from H, hydroxyl and methyl; R e R is selected from H, methyl, ethyl, cyclopropyl, cyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NR'R", methoxy, ethoxy, C1-C6 alkyl and 3-6 membered cyclic hydrocarbon groups, wherein R' and R" are each independently selected from H and methyl.
[0667] In some embodiments, the compound is selected from the following compounds:
[0668] In some embodiments, the compound is selected from the following compounds:
[0669] wherein Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group, and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group, or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0670] In some embodiments, the compound is selected from the following compounds:
[0671] Where,
[0672] Y4 is selected from the group consisting of: C, CH and N;
[0673] Y6 is selected from the group consisting of: C, CH, and N;
[0674] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0675] R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0676] n is 0, 1, 2, 3 or 4.
[0677] In some embodiments, the compound is selected from the following compounds:
[0678] Where,
[0679] Y1 is selected from the group consisting of: C, CH and N;
[0680] Y4 is selected from the group consisting of: C, CH and N;
[0681] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0682] R 15Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0683] n is 0, 1, 2, 3 or 4.
[0684] In some embodiments, the compound is selected from the following compounds:
[0685] Where,
[0686] Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S;
[0687] R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0688] n is 0, 1, 2, 3 or 4.
[0689] In some embodiments, the compound is selected from the following compounds:
[0690] Where,
[0691] Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S;
[0692] R 16is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0693] n is 0, 1, 2, 3 or 4.
[0694] In some embodiments, the compound is selected from the following compounds:
[0695] Where,
[0696] Y4 is selected from the group consisting of: C, CH and N;
[0697] Y6 is selected from the group consisting of: C, CH, and N;
[0698] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0699] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ;
[0700] D2 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0701] D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ;
[0702] The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory;
[0703] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0704] Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0705] Each R g is independently selected at each occurrence from the group consisting of H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0706] Or R on the same carbon atom f and R gForming oxo (=O) or thio (=S);
[0707] Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
[0708] In some embodiments, D2 is selected from the group consisting of: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、 and
[0709] In some embodiments, the compound is selected from the following compounds:
[0710] Where,
[0711] Y1 is selected from the group consisting of: C, CH and N;
[0712] Y4 is selected from the group consisting of: C, CH and N;
[0713] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0714] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ;
[0715] D2 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0716] D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ;
[0717] The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory;
[0718] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0719] Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0720] Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0721] Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S);
[0722] Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
[0723] In some embodiments, D2 is selected from the group consisting of: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、 and
[0724] In some embodiments, the compound is selected from the following compounds:
[0725] Where,
[0726] Y4 is selected from the group consisting of: C, CH and N;
[0727] Y6 is selected from the group consisting of: C, CH, and N;
[0728] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0729] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ;
[0730] D2 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0731] D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f )p and (CR f R g ) p ;
[0732] The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory;
[0733] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally replaced by 1, substituted with 2 or 3 substituents selected from F, hydroxy and cyano;
[0734] Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0735] Each R gis independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0736] Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S);
[0737] Each p is independently 1, 2, 3 or 4, preferably 1 or 2;
[0738] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0739] In some embodiments, in Formula XIVa, D2 is selected from the group consisting of: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、 and
[0740] In some embodiments, the compound is selected from the following compounds:
[0741] Where,
[0742] Y1 is selected from the group consisting of: C, CH and N;
[0743] Y4 is selected from the group consisting of: C, CH and N;
[0744] Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S;
[0745] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ;
[0746] D2 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p 、(CR f R g ) p 、C(O)-NRe、N-NR e , CR f -NR e 、 and
[0747] D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ;
[0748] The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory;
[0749] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0750] Each Rf is independently selected at each occurrence from the group consisting of H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0751] Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0752] Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S);
[0753] Each p is independently 1, 2, 3 or 4, preferably 1 or 2;
[0754] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0755] In some embodiments, in Formula XIVb, D2 is selected from the group consisting of: O, S, S(O), S(O)2, N, NR e 、(CR f) p 、(CR f R g ) p 、 and
[0756] In some embodiments, the compound is selected from the following compounds:
[0757] Where,
[0758] X2 is C;
[0759] Y6 is selected from the group consisting of: C, CH, and N;
[0760] Ring F is a 5- or 6-membered cycloalkyl, a 5- or 6-membered heterocyclyl, a phenyl group, or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heterocyclyl group or the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S;
[0761] R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0762] n is 0, 1, 2 or 3.
[0763] In some embodiments, the compound is selected from the following compounds:
[0764] Where,
[0765] X2 is C;
[0766] Y6 is selected from the group consisting of: C, CH, and N;
[0767] Ring F is a 5- or 6-membered cycloalkyl, a 5- or 6-membered heterocyclyl, a phenyl group, or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heterocyclyl group or the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S;
[0768] Y7, Y8 and Y9 are independently selected from: a bond, O, S, S(O), S(O)2, N, NR e , CR f and CR f R g , provided that at most one of Y7, Y8 and Y9 is a bond, Y7 and Y8, Y8 and Y9 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory,
[0769] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano;
[0770] Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0771] Each R gis independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0772] Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S);
[0773] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
[0774] In some embodiments, the compound is selected from the following compounds:
[0775] Where,
[0776] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O);
[0777] D2 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O);
[0778] D3 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O);
[0779] D4 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); and wherein the ring in which D1, D2, D3 and D4 are located satisfies the bond valence theory and contains at most two C(=O) and three N atoms;
[0780] Each R e Each occurrence is independently selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, oxo, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0781] Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time;
[0782] R1 is selected from: cyano and -C(O)NR'R";
[0783] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0784] R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic;
[0785] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl;
[0786] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;
[0787] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclic group; the 4-6 membered heterocyclic group contains 1 or 2 heteroatoms selected from N and O;
[0788] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0789] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0790] R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen;
[0791] R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl;
[0792] R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy;
[0793] R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl;
[0794] Each p is independently 1, 2, 3 or 4.
[0795] In some embodiments, R e Selected from H, methyl, difluoromethyl, trifluoromethyl, deuterated methyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl.
[0796] In some embodiments, in XVa, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
[0797] In some embodiments, the compound is selected from the following compounds:
[0798] Where,
[0799] Where,
[0800] D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O);
[0801] D2 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O);
[0802] D3 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O);
[0803] D4 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); and wherein the ring in which D1, D2, D3 and D4 are located satisfies the bond valence theory and contains at most two C(=O) and three N atoms;
[0804] Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, oxo, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0805] Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time;
[0806] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0807] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0808] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0809] R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen;
[0810] R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl;
[0811] R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy;
[0812] R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl;
[0813] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group, and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group, or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group;
[0814] Each p is 0, 1, 2, 3 or 4.
[0815] In some embodiments, in XVb, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
[0816] In some embodiments, R e Selected from H, methyl, difluoromethyl, trifluoromethyl, deuterated methyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl.
[0817] In some embodiments, the compound is selected from the following compounds:
[0818] Where,
[0819] D1 is selected from: N and CR f ;
[0820] D4 is selected from: N and CR f , and D1 and D4 are not N at the same time;
[0821] R e is selected from the group consisting of: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0822] Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time;
[0823] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0824] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl;
[0825] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;
[0826] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclic group; the 4-6 membered heterocyclic group contains 1 or 2 heteroatoms selected from N and O;
[0827] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0828] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0829] R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen;
[0830] R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl;
[0831] R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy;
[0832] R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl;
[0833] R h is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy.
[0834] In some embodiments, R e Selected from H, methyl, difluoromethyl, trifluoromethyl, deuterated methyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl.
[0835] In some embodiments, the compound is selected from the following compounds:
[0836] Where,
[0837] D1 is selected from: N and CR f ;
[0838] D4 is selected from: N and CR f , and D1 and D4 are not N at the same time
[0839] R eis selected from the group consisting of: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano;
[0840] Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time;
[0841] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0842] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0843] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0844] R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen;
[0845] R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl;
[0846] R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy;
[0847] R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl;
[0848] R h Selected from: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0849] R i Selected from: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy;
[0850] p is 1, 2, or 3.
[0851] q is 0, 1, 2, 3 or 4.
[0852] In some embodiments, R e Selected from H, methyl, difluoromethyl, trifluoromethyl, deuterated methyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2OCH3 and acetyl.
[0853] In some embodiments, the compound is selected from the following compounds:
[0854] In another aspect, the present disclosure provides a compound represented by the following formula Ya,
[0855] Where,
[0856] X1 is selected from: O and NR a ;
[0857] R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic;
[0858] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0859] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;
[0860] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; each of the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from N and O;
[0861] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0862] R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen;
[0863] R 10 Selected from: H, halogen and substituted or unsubstituted alkyl.
[0864] In another aspect, the present disclosure provides a method for preparing a compound represented by formula Ya, comprising the following steps:
[0865] (i) palladium-catalyzed borate coupling under alkaline conditions to convert the halogen Hal1 in formula Ya-1 to QBQ to obtain Ya-2;
[0866] (ii) converting Ya-2 into the potassium trifluoroborate salt of Ya-3 in an organic solvent at room temperature;
[0867] (iii) using a chlorination agent to convert Ya-3 into Ya under acid catalysis in an organic solvent,
[0868] Where,
[0869] X1 is selected from: O and NR a ; Among them, R a Selected from H and C1-C4 alkyl;
[0870] R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic;
[0871] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S;
[0872] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;
[0873] Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; each of the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from N and O;
[0874] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0875] R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen;
[0876] R 10 is selected from: H, halogen, and substituted or unsubstituted alkyl;
[0877] Hal1 is a halogen;
[0878] QBQ is boric acid or a boric acid ester;
[0879] Pg is a nitrogen protecting group.
[0880] In some embodiments, the organic solvent in step (ii) is selected from polar organic solvents. In some embodiments, the organic solvent in step (ii) is selected from methanol, ethanol, acetone and acetonitrile. In some embodiments, the organic solvent in step (ii) is acetonitrile.
[0881] In some embodiments, the organic solvent in step (iii) is selected from polar organic solvents. In some embodiments, the organic solvent in step (iii) is selected from acetonitrile, acetone, 1,2-dichloroethane, dioxane and cyclopentyl methyl ether.
[0882] In yet another aspect, the present disclosure provides a compound represented by formula Za,
[0883] Wherein, Pg is a nitrogen protecting group.
[0884] In some embodiments, Pg is Boc.
[0885] In another aspect, the present disclosure provides a method for preparing a compound represented by formula Za, comprising the following steps:
[0886] (i) palladium-catalyzed borate coupling under alkaline conditions to convert the halogen Hal1 of formula Za-1 to QBQ to obtain Za-2;
[0887] (ii) adding potassium bifluoride aqueous solution to convert QBQ into potassium trifluoroborate in an organic solvent at room temperature to obtain Za-3;
[0888] (iii) using a chlorination agent to convert Za-3 into Za under acid catalysis in an organic solvent,
[0889] In the formula, Hal1 is a halogen; QBQ is boronic acid or boronic ester; and Pg is a nitrogen protecting group.
[0890] In some embodiments, the organic solvent in step (ii) is selected from polar organic solvents. In some embodiments, the organic solvent in step (ii) is selected from methanol, ethanol, acetone and acetonitrile. In some embodiments, the organic solvent in step (ii) is acetonitrile.
[0891] In some embodiments, the organic solvent in step (iii) is selected from polar organic solvents. In some embodiments, the organic solvent in step (iii) is selected from acetonitrile, acetone, 1,2-dichloroethane, dioxane and cyclopentyl methyl ether.
[0892] The present disclosure also includes pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, isotopic substitutions, polymorphs, prodrugs, or metabolites of the compounds of the above formulae.
[0893] As used herein, "stereoisomers" refer to compounds composed of the same atoms, bonded by the same bonds, but having different three-dimensional structures. The present disclosure is intended to encompass various stereoisomers and mixtures thereof.
[0894] When the compounds of the present disclosure contain olefinic double bonds, and unless specified otherwise, it is intended that the compounds of the present disclosure include both E- and Z- geometric isomers.
[0895] "Tautomer" refers to an isomer formed by a proton shift from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compounds of the present disclosure are intended to be encompassed within the scope of the present disclosure.
[0896] The compounds of the present disclosure or their pharmaceutically acceptable salts may contain one or more chiral carbon atoms and may therefore produce enantiomers, diastereomers and other stereoisomeric forms. Each chiral carbon atom can be defined as (R)- or (S)- based on stereochemistry. The present disclosure is intended to include all possible isomers, as well as racemates and optically pure forms thereof. The compounds of the present disclosure may be prepared using racemates, diastereomers or enantiomers as starting materials or intermediates. Optically active isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as crystallization and chiral chromatography.
[0897] Conventional techniques for the preparation / isolation of individual isomers include chiral synthesis from appropriate optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high performance liquid chromatography, see, for example, GeR a ld Gübitz and Martin G.Schmid(Eds.),ChiR a SepaR a tions,Methods and Protocols,Methods in Molecular Biology,Vol.243,2004;AMStalcup,ChiR a SepaR a tions, Annu.Rev.Anal.Chem.3: 341-63, 2010; Fumiss et al. (eds.), VOGEL'S ENCYCLOPEDIA OF PR a CTICAL ORGANIC CHEMISTRY. sup. TH ED., Longman Scientific and Technical Ltd., Essex, 1991, 809-816; Heller, Acc. Chem. Res. 1990, 23, 128, the disclosures of which are incorporated herein by reference in their entirety.
[0898] The present disclosure also includes all suitable isotopic substitutions (or isotopic variants) of the compounds of the present disclosure or their pharmaceutically acceptable salts. Isotopic variants of the compounds of the present disclosure or their pharmaceutically acceptable salts are defined as those in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass commonly found in nature. Isotopes that can be incorporated into the compounds of the present disclosure and their pharmaceutically acceptable salts include, but are not limited to, isotopes of H, C, N, and O, for example 2 H. 3 H. 11 C.13 C. 14 C. 15 N. 17 O. 18 O. 35 S. 18 F. 36 Cl and 125 I. Isotopic variations of the compounds of the present disclosure or pharmaceutically acceptable salts thereof can be prepared by conventional techniques using appropriate isotopic variations of suitable reagents.
[0899] In the present disclosure, the term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0900] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without the side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates; organic acid salts include, but are not limited to, formate, acetate, 2,2-dichloroacetate, trifluoroacetate, propionate, hexanoate, octanoate, decanoate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, alginate, ascorbate, salicylate, 4-aminosalicylate, and naphthalene disulfonate. These salts can be prepared by methods known in the art.
[0901] "Pharmaceutically acceptable base addition salts" refer to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. The salt derived from organic base includes but is not limited to following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0902] As used herein, the term "prodrug" refers to compounds that are metabolized (i.e., converted in vivo) into pharmacologically active compounds of the present disclosure after administration. When the compounds of the present disclosure themselves are poorly absorbed from the gastrointestinal tract, their bioavailability can be improved by preparing them into prodrugs. Examples of prodrugs of the compounds of the present disclosure may include simple esters of compounds containing carboxyl groups (e.g., esters obtained by condensation with C1-C4 alcohols according to methods known in the art); esters of compounds containing hydroxyl groups (e.g., esters obtained by condensation with C1-C4 monocarboxylic acids, C3-C6 dicarboxylic acids, or anhydrides thereof, such as succinic anhydride or fumaric anhydride according to methods known in the art); imines of compounds containing amino groups (e.g., imines obtained by condensation with C1-C4 aldehydes or ketones according to methods known in the art); carbamates of compounds containing amino groups, such as those described by Leu et al. (J. Med. Chem., 42:3623-3628 (1999)) and Greenwald et al. (J. Med. Chem., 42:3657-3667 (1999)); acetals or ketals of compounds containing hydroxyl groups (e.g., those obtained by condensation with chloromethyl methyl ether or chloromethyl ethyl ether according to methods known in the art).
[0903] III. Compound Preparation
[0904] Herein, the compound of formula I can be prepared by the following general synthetic route:
[0905] R1-R in each structural formula 10 、R 11, X1-X3, Y1-Y6 are as defined in any of the preceding embodiments; G is boric acid, potassium trifluoroborate or borate ester, etc.; X is a halogen, preferably Br or I; R1' is a conversion functional group of R1, preferably a cyano group or an ester group, which can be converted into R1 under appropriate conditions; Pg is a nitrogen protecting group, preferably tert-butyloxycarbonyl (tBuOC(O)-).
[0906] The above methods include:
[0907] When both R1 and R1' are cyano groups, the compound of Formula I can be obtained via Steps 1 and 3. In Step 1, Formulas Xa and Xb are coupled using a palladium catalyst, a ligand, and a base to obtain Formula Xc. When R1' and / or R2 are not H, Formula Xc typically contains a pair of axial chiral isomers. In Step 3, Pg is removed from Formula Xc under appropriate conditions to obtain the compound of Formula I.
[0908] When R1 is CONH2 and R1' is cyano, the compound of Formula I can be obtained via Steps 1, 2, and 3. In Step 1, Formulas Xa and Xb are coupled using a palladium catalyst, a ligand, and a base to obtain Formula Xc. When R1' and / or R2 are not H, Formula Xc typically contains a pair of axial chiral isomers. In Step 2, Formula Xc is hydrolyzed to an amide using a copper catalyst, preferably copper acetate, to obtain Formula Xd. In Step 3, Pg is removed from Formula Xd under appropriate conditions to obtain the compound of Formula I.
[0909] When R1 is CONR'R", R' and R" are different from each other and are both H, and R1' is a cyano group or a methyl formate group (-COOCH3), the compound of formula I can be obtained through the reaction sequence of step 1, step 4, step 5 and step 3. In step 1, formula Xa and Xb are coupled with a palladium catalyst, a ligand and a base to obtain formula Xc. When R1' and / or R2 are not H, formula Xc usually contains a pair of axial chiral isomers. In step 4, formula Xc is hydrolyzed with an inorganic base to obtain formula Xc', and the inorganic base is preferably sodium hydroxide, lithium hydroxide and potassium hydroxide. In step 5, formula Xc' is condensed with R'R"NH with a condensing agent to obtain formula Xd. In step 3, formula Xd is subjected to appropriate conditions to remove Pg to obtain a compound of formula I.
[0910] Other compounds disclosed herein can be prepared by referring to the above reaction scheme.
[0911] When G in formula Xa is BF3K and R7 is chlorine, formula Ya can be synthesized by the following route 2:
[0912] R3-R6, R8-R in each structural formula 10 and X1 are as defined in any of the preceding embodiments; preferably, R8 is F, R9 and R 10is H, R3 is phenyl, R4 or R5 together with R6 and the C and N to which they are attached form Formula Za can be synthesized by the following route 3:
[0913] In the synthetic routes 2 and 3, Hal1 is a halogen, preferably Br or I; QBQ is boric acid or a boric acid ester, preferably boric acid (B(OH)2), pinacol boric acid ester Diisopropyl borate or Pg is a nitrogen protecting group, preferably tert-butyloxycarbonyl (tBuOC(O)-). In Synthetic Schemes 2 and 3, Step 1: The halogen (Hal1) of Formula Ya-1 or Formula Za-1 is converted to a boronic acid or boronic ester (QBQ), which can be obtained by palladium-catalyzed coupling of the boronic ester under alkaline conditions. In the palladium-catalyzed coupling, the palladium catalyst is preferably [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex, the boronic ester is preferably pinacol borate, the base is preferably potassium acetate, the reaction solvent is preferably toluene, and the reaction temperature is preferably 75-105°C. Step 2: Boric acid or boronic ester (QBQ) is added to an organic solvent, preferably an alcohol, with aqueous potassium bifluoride solution and converted to the potassium trifluoroborate salt Ya-3 at room temperature. Step 3: Ya-3 is chlorinated using a chlorination agent in an organic solvent under acid catalysis to obtain Ya; the organic solvent is preferably acetonitrile, the chlorination agent is preferably N-chlorosuccinimide, the acid is preferably p-toluenesulfonic acid, and the reaction temperature is preferably -10 to 40 degrees.
[0914] IV. Pharmaceutical Compositions, Methods, Uses, and Other Embodiments
[0915] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug or metabolite thereof, and a pharmaceutically acceptable carrier or excipient.
[0916] In another aspect, the present disclosure provides a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure for the preparation of a medicament for treating or preventing diseases mediated by the interaction of YAP / TAZ with TEAD.
[0917] In another aspect, the present disclosure provides a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure for use in treating or preventing a disease. In some embodiments, the present disclosure also provides a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure for use in treating or preventing diseases mediated by the interaction of YAP / TAZ with TEAD.
[0918] In another aspect, the present disclosure provides a method for treating or preventing a disease mediated by the interaction of YAP / TAZ with TEAD, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure.
[0919] Compounds of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure, or pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, isotopic substitutions, polymorphs, prodrugs or metabolites thereof, are inhibitors of the interaction between YAP / TAZ and TEAD, more specifically, inhibitors of the interaction between YAP and TEAD. Therefore, the compounds of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure, or pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, isotopic substitutions, polymorphs, prodrugs or metabolites thereof, can be used to treat or prevent diseases mediated by the interaction of YAP / TAZ with TEAD.
[0920] Herein, "diseases mediated by the interaction of YAP / TAZ and TEAD" refers to diseases in which the interaction of YAP / TAZ and TEAD is involved in the occurrence and / or development of the disease, and which can be alleviated, treated and / or prevented by inhibiting the expression and / or activity of YAP and TEAD or by inhibiting or blocking the YAP-TEAD protein interaction.
[0921] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is tumor, liver fibrosis and kidney fibrosis.
[0922] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is a benign tumor.
[0923] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is a malignancy, such as cancer or sarcoma.
[0924] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is a solid tumor or a hematological tumor.
[0925] In some embodiments, the disease mediated by the interaction of YAP / TAZ with TEAD is mesothelioma (e.g., pleural mesothelioma (such as malignant pleural mesothelioma), peritoneal mesothelioma, pericardial mesothelioma or sheath mesothelioma), cervical squamous cell carcinoma, endometrial cancer, bladder urothelial carcinoma, skin squamous cell carcinoma, poroma (e.g., benign poroma), porocarcinoma, epithelioid hemangioendothelioma, breast cancer (e.g., triple-negative breast cancer), lung cancer (e.g., non-small cell lung cancer), ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, prostate cancer. , stomach cancer, esophageal cancer (e.g., esophageal squamous cell carcinoma or esophageal adenocarcinoma), liver cancer (e.g., hepatocellular carcinoma or hepatoblastoma), bile duct cancer, neurilemmoma, kidney cancer, sarcoma (e.g., rhabdomyosarcoma, embryonal rhabdomyosarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma, Kaposi's sarcoma, and soft tissue sarcomas (such as rare soft tissue sarcomas)), bone cancer, brain cancer (e.g., ependymoma (e.g., supratentorial ependymoma, such as supratentorial ependymoma in children), neuroblastoma, medulloblastoma, glioma, or meningioma), or head and neck cancer (e.g., head and neck squamous cell carcinoma).
[0926] In some embodiments, the disease mediated by the interaction of YAP / TAZ and TEAD is mesothelioma (e.g., pleural mesothelioma (such as malignant pleural mesothelioma), peritoneal mesothelioma, pericardial mesothelioma, or sheath mesothelioma). In some embodiments, the disease mediated by the interaction of YAP / TAZ and TEAD is malignant pleural mesothelioma (MPM), which is a rare malignant tumor of the chest. Abnormal activation of the Hippo-YAP pathway is present in approximately 70% of MPM patients and is considered to be an important cancer driver gene. Reducing the activity of the Hippo-YAP pathway through biological means and chemical small molecules has shown good activity in inhibiting tumor growth.
[0927] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is breast cancer (e.g., triple-negative breast cancer).
[0928] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is lung cancer (eg, non-small cell lung cancer).
[0929] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is colorectal cancer.
[0930] In some embodiments, the disease mediated by the interaction of YAP / TAZ and TEAD is pancreatic cancer (eg, pancreatic ductal adenocarcinoma (PDAC)).
[0931] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is gastric cancer.
[0932] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is liver cancer (eg, hepatocellular carcinoma or hepatoblastoma).
[0933] In some embodiments, the disease mediated by the interaction of YAP / TAZ and TEAD is brain cancer (e.g., ependymoma (e.g., supratentorial ependymoma, such as supratentorial ependymoma in children), neuroblastoma, medulloblastoma, glioma, or meningioma).
[0934] In some embodiments, the disease mediated by the interaction between YAP / TAZ and TEAD is head and neck cancer (e.g., head and neck squamous cell carcinoma).
[0935] The YAP signaling pathway can confer resistance to a variety of targeted anticancer drugs by inducing tumor cell dormancy and resisting apoptosis. Therefore, inhibiting the Hippo-YAP signaling pathway can increase the sensitivity of tumor cells to targeted drugs. Furthermore, Hippo-YAP, a pathway that promotes tumor cell growth, is overactivated in multiple drug-resistant tumor models. Inhibiting its activity can significantly increase the sensitivity of treated tumor cells to related inhibitors. Therefore, in some embodiments, the compounds of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure or pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, isotopic substitutions, polymorphs, prodrugs or metabolites thereof can be used to increase the sensitivity of treated tumor cells to targeted drugs (such as EGFR inhibitors, inhibitors targeting BRAF, inhibitors targeting MEK, etc.), thereby improving the therapeutic effect of these targeted drugs.
[0936] As used herein, the terms "administer," "administer," "dosing," and the like refer to methods that enable a compound or pharmaceutical composition to be delivered to the desired site for biological action. Methods of administration known in the art can be used in the present disclosure. These methods include, but are not limited to, oral administration, intraduodenal administration, parenteral administration (including intrapulmonary, intranasal administration; intrathecal, intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. Those skilled in the art are familiar with administration techniques that can be used for the compounds and methods described herein, such as those discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. In a preferred embodiment, the compounds of the present disclosure, their pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, isotopically substituted products, polymorphs, prodrugs or metabolites, or pharmaceutical compositions thereof, are administered orally.
[0937] In some embodiments, a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb, and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition thereof, is used in combination with other pharmacologically active compounds, for example, for the treatment of cancer. For example, in some embodiments, a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb, and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug, or metabolite thereof, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug, or metabolite of the present disclosure, The pharmaceutical composition prescribed is administered simultaneously, sequentially or separately in combination with one or more pharmacologically active compounds selected from the following: chemotherapeutic agents, for example, mitotic inhibitors such as taxanes (e.g., paclitaxel or docetaxel), vinca alkaloids (e.g., vincristine, vinblastine, vinorelbine or vinflunine), other anticancer agents such as metal platinum complexes (e.g., cisplatin, carboplatin or oxaliplatin), antimetabolites (e.g., pyrimidine antagonists such as 5-fluorouracil, 5-fluoro-2-4(1H,3H)-pyrimidinedione (5FU) or gemcitabine), hormonal antitumor drugs (e.g., flutamide), etc. In some embodiments, a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure is used together with tumor immunotherapy drugs well known in the art (such as anti-PD1 antibodies) for the treatment of cancer.In some embodiments, a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb, and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug or metabolite thereof, or a pharmaceutical composition of the present disclosure, is used in combination with conventional radiation therapy.
[0938] As used herein, the terms "combination," "drug combination," "drug combination," or "combination therapy" refer to a medical therapy achieved by mixing or combining more than one active ingredient, and include both fixed and non-fixed combinations of active ingredients, as well as combinations of two or more different therapeutic approaches. The term "fixed combination" means that at least one compound described herein and at least one other active ingredient are administered to a patient simultaneously as a single entity or single dosage form. The term "non-fixed combination" means that at least one compound described herein and at least one other active ingredient are administered to a patient simultaneously, in combination, or sequentially at variable intervals as separate entities. This also applies to cocktail therapies, e.g., administration of three or more active ingredients.
[0939] In the present disclosure, the pharmaceutical composition contains a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb and XIVc) of the present disclosure or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof and a pharmaceutically acceptable carrier or excipient (which is a medium generally accepted in the art for delivering biologically active compounds to mammals (e.g., humans)). The purpose of preparing the active compound into a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient and thus exert biological activity. Generally speaking, the pharmaceutical composition of the present disclosure contains 0.1% to 99.5% by weight of the active pharmaceutical ingredient. In some embodiments, the pharmaceutical compositions of the present disclosure contain 0.5%-90% by weight, e.g., 1%, 1.5%, 2%, 5%, 10%, 15%, 20%, 25%, 30% or 50% by weight of the pharmaceutically active ingredient.
[0940] In some embodiments, the pharmaceutical compositions of the present disclosure contain, in addition to a compound of Formula I or any subformula thereof (including but not limited to Ia, Ib, IIa, IIb, IIc, IId, IIe, IIIa, IIIb, IVa, IVb, IVc, XI, XIa, XIb, XIIa, XIIb, XIIc, XIId, XIIe, XIIIa, XIIIb, XIVa, XIVb, and XIVc) of the present disclosure, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted compound, polymorph, prodrug thereof or metabolites thereof, it also contains other known anticancer agents, including but not limited to chemotherapeutic agents, such as mitotic inhibitors, such as taxane compounds (such as paclitaxel or docetaxel), vinca alkaloids (such as vincristine, vinblastine, vinorelbine or vinflunine), other anticancer agents such as metal platinum complexes (such as cisplatin, carboplatin or oxaliplatin), antimetabolites (such as pyrimidine antagonists, such as 5-fluorouracil, 5-fluoro-2-4(1H,3H)-pyrimidinedione (5FU), gemcitabine), hormonal antitumor drugs (such as flutamide), tumor immunotherapy drugs (such as anti-PD1 antibodies), etc.
[0941] In another aspect, the present disclosure also provides the following embodiments:
[0942] 1. A compound represented by the following formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof:
[0943] Where:
[0944] X1 is selected from: O and NR a ;
[0945] X2 is selected from: C or N;
[0946] X3 is selected from: C or N;
[0947] Y5 is selected from: bond, O, S, N, S(=O), SO2, CHR 13 、C(R 13 2. CR 13 , -OCH2-, -NCH2-, -CH2CH2- or NR 12 ;
[0948] Y1, Y4 and Y6 are independently selected from: a bond, O, N, C, S, -S(O)-, -SO2-, CH, CH2, NH, CHR 13 、CHR 13 、C(R 13 )2 or NR 12; or, when Y1, Y4 and Y6 are arbitrarily selected from C(R 13 )2, two R 13 The C atom connected thereto may form a substituted or unsubstituted 3-8 membered hydrocarbon ring or a substituted or unsubstituted 4-9 membered heterocyclic ring, thereby forming a spiro ring structure with ring B; or, the ring atom in Y1 or Y6 and the ring atom in Y4 and the substituent R connected to the ring atom 13 and / or R 12 forming a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, a substituted or unsubstituted 4-9 membered heterocyclic group, a substituted or unsubstituted 6-10 membered aryl group, or a substituted or unsubstituted 5-10 membered heteroaryl group, thereby forming a parallel ring structure with ring B;
[0949] Ring B is a 5-membered or 6-membered heterocyclic ring, carbocyclic ring or heteroaromatic ring; Ring B may be optionally replaced by an uncyclic R 13 and / or R 12 In addition to substitution, it may be optionally substituted by 1-3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R" and substituted or unsubstituted alkoxy;
[0950] R1 is selected from: cyano and -C(=O)NR'R";
[0951] R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy;
[0952] R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic;
[0953] R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1-3 heteroatoms selected from O, N and S;
[0954] R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;
[0955] Alternatively, R4 or R5 together with R6 and the C and N to which they are attached form a substituted or unsubstituted 4-12-membered monocyclic or cyclic heterocyclic group, a 6-12-membered bridged heterocyclic group or a 6-12-membered spiro heterocyclic group; each of the 4-12-membered monocyclic or cyclic heterocyclic group, the 6-12-membered bridged heterocyclic group and the 6-12-membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from O or N;
[0956] R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0957] R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl;
[0958] R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen;
[0959] R 10 is selected from: H, halogen, and substituted or unsubstituted alkyl;
[0960] R 11 is selected from the group consisting of: H, hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R", and substituted or unsubstituted alkoxy;
[0961] Each R 12 independently selected from the group consisting of: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-14 membered aryl-S(O)2-, 4-9 membered heterocyclyl, NR'R"-C(O)-, C3-C8 cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl;
[0962] Each R 13 independently selected from: H, halogen, oxo (=O), substituted or unsubstituted C1-C4 acyl, -OH, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C6-14 aryl-S(O)2-, C3-C6 cycloalkyl-C(O)- and -C(O)-NR'R";
[0963] And R 13 or R 12 After participating in the ring formation, its ring atoms may be optionally substituted by 1-3 heteroatoms selected from O, N and S;
[0964] R' and R" are each independently selected from H, C1-C4 alkyl, C1-C4 alkyl-S(O)2-, halogenated C1-C4 alkyl;
[0965] Ra is selected from H or C1-C4 alkyl.
[0966] Here, the dotted line indicates the presence or absence of a double bond.
[0967] 2. The compound according to Embodiment 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein the compound of Formula I has the structure shown in Formula Ia below:
[0968] Wherein, Y1 and Y4 are independently selected from: bond, O, N, CH, CH2, CHR 13 , CR 13 、C(R 13 )2 or NR 12 ; and Y1 and Y4 are not a bond or O at the same time;
[0969] Y5 and Y6 are independently selected from: O, N, S, -S(O)-, -SO2-, CH, CH2, NH, CHR 13 , CR 13 、C(R 13 )2 or NR 12 ;
[0970] Ring B, R1-R 13 , X2 and X3 are as defined in embodiment 1;
[0971] Here, the dotted line indicates the presence or absence of a double bond.
[0972] 3. The compound according to Embodiment 1 or 2, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein the compound of Formula I has the structure shown in Formula Ib below:
[0973] wherein Y1, Y4, Y5 and Y6 are as defined in Embodiment 2; R1-R3, R7-R 13 , X2 and X3 are as defined in Embodiment 1.
[0974] Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group, or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group; the 4-12 membered monocyclic or cyclic heterocyclic group, the substituted or unsubstituted 6-12 membered bridged heterocyclic group or the substituted or unsubstituted 6-12 membered spiro heterocyclic group may optionally contain 1, 2 or 3 heteroatoms selected from N and O;
[0975] Here, the dotted line indicates the presence or absence of a double bond.
[0976] 4. The compound according to any one of embodiments 1-3, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that when Y1 or Y4 or Y5 or Y6 is NR 12 When R 12 Selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, C3-C8 cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl and C1-C4 alkyl are optionally substituted with 1-3 substituents selected from F, hydroxyl and cyano.
[0977] 5. The compound according to any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that when Y1 or Y4 or Y5 or Y6 is NR 12 When R 12 Selected from: H, acetyl, propionyl, C1-C3 alkoxy, C1-C3 alkyl-S(O)2-, 4-6 membered heterocyclyl, C3-C5 cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkyl is arbitrarily substituted with 1-3 substituents selected from F, hydroxyl and cyano.
[0978] 6. A compound according to any one of embodiments 1 to 5, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that when Y1 or Y4 or Y5 or Y6 is arbitrarily selected from CHR 13 , CR 13 or C(R 13 )2, R 13Selected from: H, halogen, oxo (=O), substituted or unsubstituted C1-C4 acyl, -OH, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, C3-C6 cycloalkyl-C(O)- and -C(O)-NR'R". R' and R" are each independently selected from H, C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy and C1-C6 alkyl are optionally substituted by 1-3 substituents selected from F, hydroxyl and cyano.
[0979] 7. A compound according to any one of embodiments 1-6, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that when Y1 or Y4 or Y5 or Y6 is arbitrarily selected from CHR 13 , CR 13 or C(R 13 )2, R 13 Selected from: H, fluorine, chlorine, oxo (=O), C1-C4 acyl, -OH, cyano, C1-C4 alkoxy, C1-C6 alkyl, C1-C4 alkyl-S(O)2-, and C3-C4 cycloalkyl-C(O)-.
[0980] 8. The compound according to Embodiment 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein the compound of Formula I has the structure shown in Formula IIa below:
[0981] Where, R1-R 13 , X2, X3, Y1 and Y5 are as defined in embodiment 1;
[0982] Y4 is selected from: C, CH or N;
[0983] Y6 is selected from: C, CH or N;
[0984] Ring D is a C3-C8 cycloalkyl, a C4-C9 heterocyclyl, a C5-C10 heteroaryl or a C6-C10 aryl; the C4-C9 heterocyclyl and C5-C10 heteroaryl may optionally contain 1-3 heteroatoms selected from O, N and S;
[0985] R 15Selected from: H, halogen, oxo (=O), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", -C(O)-NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C6-C14 aryl-S(O)2-, 4-9 membered heterocyclyl, NR'R"-C(O)-, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1-3 substituents selected from F, hydroxy and cyano;
[0986] Each n is independently 0, 1, 2, 3 or 4;
[0987] Here, the dotted line indicates the presence or absence of a double bond.
[0988] 9. The compound according to Embodiment 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein the compound of Formula I has the structure shown in the following Formula IIb:
[0989] Where, R1-R 13 , X2, X3, Y5 and Y6 are as defined in embodiment 1;
[0990] Y1 is selected from: C, CH or N;
[0991] Y4 is selected from: C, CH or N;
[0992] Ring D, R 15 and n is as defined in Embodiment 8;
[0993] Here, the dotted line indicates the presence or absence of a double bond.
[0994] 10. The compound according to embodiment 8 or 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that ring D is a C3-C6 cycloalkyl, a C4-C6 heterocyclyl, a C5-C8 heteroaryl or a C6-C10 aryl; the C4-C6 heterocyclyl and C5-C8 heteroaryl may optionally contain 1-3 heteroatoms selected from O, N and S; R 15Selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxyl, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", -C(O)-NR'R", 4-9 membered heterocyclyl, NR'R"-C(O)-, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1-3 substituents selected from F, hydroxyl and cyano; R' and R" are each independently selected from H, C1-C4 alkyl; n is 0, 1 or 2.
[0995] 11. The compound according to any one of embodiments 8-10, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", -C(O)-NR'R", NR'R"-C(O)-, C3-C8 cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H, C1-C4 alkyl; n is 0 or 1.
[0996] 12. The compound according to Embodiment 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug, or metabolite thereof, wherein the compound of Formula I has the structure shown in Formula IIc below:
[0997] Where, R1-R 13 , X2, X3, Y1, Y5 and Y6 are as defined in embodiment 1;
[0998] Ring E is a C3-C8 cycloalkyl or a C4-C9 heterocyclic group; the C4-C9 heterocyclic group may optionally contain 1-3 heteroatoms selected from O, N and S;
[0999] R 16 is selected from halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 acyl, C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1-3 substituents selected from F, hydroxy and cyano.
[1000] n is 0, 1, 2, 3 or 4;
[1001] Here, the dotted line indicates the presence or absence of a double bond.
[1002] 13. The compound according to Embodiment 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug, or metabolite thereof, wherein the compound of Formula I has the structure shown in Formula IIc below:
[1003] Where, R1-R 13 , X2, X3, Y4, Y5 and Y6 are as defined in embodiment 1;
[1004] Ring E, R 16 and n is as defined in embodiment 12;
[1005] Here, the dotted line indicates the presence or absence of a double bond.
[1006] 14. The compound according to embodiment 12 or 13, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that ring E is a C3-C6 cycloalkyl or a C4-C6 heterocyclic group; the C4-C6 heterocyclic group may optionally contain 1-3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, C1-C4 alkyl and hydroxy; n is 0 or 1.
[1007] 15. The compound according to any one of embodiments 12-15, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that ring E is cyclopropane, cyclobutane, cyclopentane, cyclohexane, oxetanyl, oxolanyl, azetidinyl or azopentanyl; R 16 Selected from H, fluorine, methyl, ethyl, hydroxyl.
[1008] 16. The compound according to embodiment 8, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein the compound of formula IIa has the structure shown in formula IIIa below:
[1009] Where, R1-R 13 , X2, X3, Y1 and Y5 are as defined in embodiment 1;
[1010] Y4 and Y6 are as described in Embodiment 8;
[1011] D1 is selected from: O, S, S(O)2, N, NRe , CR f and CR f R g ;
[1012] D2 is selected from: O, S, S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ;
[1013] D3 is selected from: O, S, S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ;
[1014] Each R e Independently selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, 4-9 membered heteroaryl, 4-9 membered heterocyclyl, NR'R"-C(O)-, C3-C6 cycloalkyl, C3-C6 cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkyl; wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy and C1-C4 alkyl are optionally substituted by 1-3 substituents selected from F, hydroxyl and cyano.
[1015] Each R f Independently selected from: H, halogen, oxo (=O), substituted or unsubstituted C1-C4 acyl, -OH, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, C3-C6 cycloalkyl-C(O)- and -C(O)-NR'R"; wherein, R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy and C1-C4 alkyl are optionally substituted by 1-3 substituents selected from F, hydroxyl and cyano.
[1016] Each R gIndependently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, -OH, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, C3-C6 cycloalkyl-C(O)- and -C(O)-NR'R"; wherein, R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1-3 substituents selected from F, hydroxyl and cyano. Each p is independently an integer of 1-4, preferably 1 or 2.
[1017] Here, the dotted line indicates the presence or absence of a double bond.
[1018] 17. The compound according to Embodiment 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug, or metabolite thereof, wherein the compound of Formula IIb has the structure shown in Formula IIIb below:
[1019] Where, R1-R 13 , X2, X3, Y5 and Y6 are as defined in embodiment 1;
[1020] Y1 and Y4 are as described in Embodiment 9;
[1021] D1, D2 and D3 are as described in Embodiment 16;
[1022] Here, the dotted line indicates the presence or absence of a double bond.
[1023] 18. The compound according to embodiment 16, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein the compound of formula IIIa has the structure shown in formula IVa below:
[1024] Where, R1-R 13 , X2, X3, Y1 and Y5 are as defined in embodiment 1;
[1025] Y4 and Y6 are as described in Embodiment 8;
[1026] D1, D2 and D3 are as described in Embodiment 16;
[1027] Ring C is as described in Embodiment 3;
[1028] Here, the dotted line indicates the presence or absence of a double bond.
[1029] 19. The compound according to embodiment 17, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein the compound of formula IIIb has the structure shown in formula IVb below:
[1030] Where, R1-R 13 , X2, X3, Y5 and Y6 are as defined in embodiment 1;
[1031] Y1 and Y4 are as described in Embodiment 9;
[1032] D1, D2 and D3 are as described in Embodiment 16;
[1033] Ring C is as described in Embodiment 3;
[1034] Here, the dotted line indicates the presence or absence of a double bond.
[1035] 20. A compound as described in any one of embodiments 1-19, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope substitute, polymorph, prodrug or metabolite thereof, characterized in that R1 is -C(=O)NR'R"; and R' and R" are each independently selected from H, C1-C4 alkyl, C1-C4 alkyl-S(O)2-, and halogenated C1-C4 alkyl.
[1036] 21. A compound as described in any one of embodiments 1-20, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R1 is -C(=O)NHR'; wherein R' is selected from H and C1-C4 alkyl.
[1037] 22. A compound as described in any one of embodiments 1-21 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R1 is -C(=O)NH2.
[1038] 23. A compound as described in any one of embodiments 1-21, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R1 is -C(=O)NHCH3.
[1039] 24. A compound as described in any one of embodiments 1-23, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R2 is selected from H, halogen, C1-C4 alkyl and C1-C4 alkoxy.
[1040] 25. A compound as described in any one of embodiments 1-24, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R2 is selected from H, halogen and methoxy.
[1041] 26. A compound as described in any one of embodiments 1-25, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R2 is selected from halogen.
[1042] 27. A compound as described in any one of embodiments 1-26, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R2 is selected from fluorine and chlorine.
[1043] 28. A compound as described in any one of embodiments 1-27, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R2 is fluorine.
[1044] 29. A compound as described in any one of embodiments 1-28, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R3 is selected from substituted or unsubstituted aryl.
[1045] 30. A compound as described in any one of embodiments 1-29, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R3 is selected from substituted or unsubstituted phenyl.
[1046] 31. A compound as described in any one of embodiments 1-30, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R3 is phenyl.
[1047] 32. A compound as described in any one of embodiments 1-31, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope substitution, polymorph, prodrug or metabolite thereof, characterized in that R4 and R5 are each independently selected from: H, substituted or unsubstituted alkyl; or R4 and R5 and the carbon atoms to which they are connected form a 3-6 membered substituted or unsubstituted ring, which optionally contains 1-3 heteroatoms selected from O, N and S.
[1048] 33. A compound as described in any one of embodiments 1-32, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R4 and R5 are each independently selected from: H, substituted or unsubstituted C1-C4 alkyl.
[1049] 34. A compound as described in any one of embodiments 1-33, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R4 and R5 are each independently selected from: H, C1-C3 alkyl.
[1050] 35. A compound as described in any one of embodiments 1-34, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R4 and R5 are each independently selected from: H, methyl.
[1051] 36. A compound as described in any one of embodiments 1-35, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R4 and R5 are both H.
[1052] 37. A compound as described in any one of embodiments 1-36, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope substitution, polymorph, prodrug or metabolite thereof, characterized in that R7 and R8 are each independently selected from: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl.
[1053] 38. A compound as described in any one of embodiments 1-37, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy.
[1054] 39. A compound as described in any one of embodiments 1-38, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R7 and R8 are each independently selected from: fluorine and chlorine.
[1055] 40. A compound as described in any one of embodiments 1-39, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R7 is chloro and R8 is fluoro.
[1056] 41. A compound as described in any one of embodiments 1-40, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R9 is selected from H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen.
[1057] 42. A compound as described in any one of embodiments 1-41, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R9 is selected from H, methyl, methoxy, hydroxyl and F.
[1058] 43. A compound as described in any one of embodiments 1-42, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R9 is H.
[1059] 44. A compound according to any one of embodiments 1-43, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 10 Selected from: H, halogen and C1-C4 alkyl.
[1060] 45. A compound according to any one of embodiments 1 to 44, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 10Selected from: H, F and methyl.
[1061] 46. A compound according to any one of embodiments 1 to 45, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 10 For H.
[1062] 47. A compound according to any one of embodiments 1 to 46, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy, wherein R' and R" are independently selected from C1-C4 alkyl.
[1063] 48. A compound according to any one of embodiments 1-47, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NCH3.
[1064] 49. A compound according to any one of embodiments 1-48, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R 11 For H.
[1065] 50. The compound of any one of embodiments 1-49, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein X2 is C.
[1066] 51. A compound as described in any one of embodiments 1-49, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that X2 is N.
[1067] 52. The compound of any one of embodiments 1-51 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein X3 is C.
[1068] 53. A compound as described in any one of embodiments 1-50, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that X3 is N.
[1069] 54. A compound as described in any one of embodiments 1-53, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that Y5 is selected from: a bond, O, S, N, CH2, CH, NH and NCH3.
[1070] 55. A compound as described in any one of embodiments 1-54, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that Y5 is O.
[1071] 56. A compound as described in any one of embodiments 1-54, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that Y5 is CH or CH2.
[1072] 57. A compound as described in any one of embodiments 1-54, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that Y5 is NH or N.
[1073] 58. A compound as described in any one of embodiments 2-7, 9, 12-13, 17 and 19-56, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug or metabolite thereof, characterized in that Y6 is selected from: a bond, O, S, N, CH, CH2, NH or NCH3.
[1074] 59. A compound as described in any one of embodiments 2-7, 8, 12, 16 and 18-53, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted, polymorph, prodrug or metabolite thereof, characterized in that Y1 is selected from: a bond, O, NH, -NCH3, CH, CH2 and -CH(CH3)-.
[1075] 60. A compound as described in any one of embodiments 1-59, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substitution, polymorph, prodrug or metabolite thereof, characterized in that R6 is selected from: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclyl, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclyl, substituted or unsubstituted 6-12 membered spirocyclyl and substituted or unsubstituted 6-12 membered spiroheterocyclyl.
[1076] 61. A compound according to any one of embodiments 1 to 60, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that R6 is H, substituted C1-C6 alkyl, substituted C1-C6 alkoxy, substituted C2-C6 alkenyl or substituted C2-C6 alkynyl, and the substituents thereof are 1-3 selected from the group consisting of: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, C1-C4 alkyl optionally substituted by halogen, -S(O)2-, sulfone, C1-C4 alkyl optionally substituted by halogen, -S(O)2- 2-NR'R", sulfonamide, -C(O)-C1-C4 alkyl, -NR'-C(O)-C1-C4 alkyl, and 6-14 membered aryl, 5-10 membered heteroaryl, C3-C8 cycloalkyl and 4-9 membered heterocyclyl optionally substituted with a substituent selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, C3-C8 cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or
[1077] R6 is a substituted C3-C8 cycloalkyl or a substituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1-3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", C1-C4 alkoxy, halogenated C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, wherein the C1-C4 alkyl and C1-C4 alkoxy are optionally substituted with 1-3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein the R' and R" are each independently selected from H and C1-C4 alkyl; or
[1078] When R6 is a substituted 6-12 membered bridged cyclic group, a substituted 6-12 membered bridged heterocyclic group, a substituted 6-12 membered spirocyclic group or a substituted 6-12 membered spiroheterocyclic group, the number of substituents thereof is 1-3 and is selected from the group consisting of: C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, cyano, C1-C4 alkyl-S(O)2-, hydroxyl, halogen and NR'R", wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl.
[1079] 62. A compound as described in any one of embodiments 1-59, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope substitution, polymorph, prodrug or metabolite thereof, characterized in that R6 is -LWZ, wherein L is a bond or a substituted or unsubstituted C1-C4 alkyl; W is a bond, a substituted or unsubstituted C1-C4 alkyl, a substituted or unsubstituted C3-C8 cycloalkyl, a substituted or unsubstituted 6-14 membered aryl, a substituted or unsubstituted 5-10 membered heteroaryl, a substituted or unsubstituted 4-9 membered heterocyclyl, a substituted or an unsubstituted 6-12 membered bridged cyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, a substituted or unsubstituted 6-12 membered spirocyclic group or a substituted or unsubstituted 6-12 membered spiroheterocyclic group; Z is hydrogen, halogen, C1-C4 alkyl, -O-C1-C4 alkyl, hydroxyl, sulfone, -S(O)2-C1-C4 alkyl, -S(O)2-NR'R", sulfonamide, cyano, -C(O)-C1-C4 alkyl, C3-C8 cycloalkyloxy or -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently H or C1-C4 alkyl.
[1080] 63. The compound of embodiment 62, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug, or metabolite thereof, wherein -LWZ is selected from the group consisting of: (wavy lines indicate bond positions)
[1081] 64. A compound as described in any one of embodiments 1-2, 4-17 and 20-62, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope substitution, polymorph, prodrug or metabolite thereof, characterized in that R4 or R5, together with R6 and the C and N to which they are attached, forms a 4-9 membered heterocyclic group that can be substituted by 1-3 substituents selected from H, deuterium, hydroxyl, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy.
[1082] 65. The compound of any one of embodiments 1-2, 4-17, 20-...
Claims
1. A compound represented by the following formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof: Where: X1 is selected from: O and NR a ; X2 is selected from: C and N; X3 is selected from: C and N; Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2、C(R 13 )、-OCH2-、-N(R 12 )CH2-, -CH2CH2- and N(R 12 ), and Y5 and Y6 are not bonds at the same time; Y1 and Y4 are independently selected from the group consisting of: a bond, O, N, C, S, -S(O)-, -C(O)-, -S(O)2-, CH, CH2, NH, C(R 13 )、CH(R 13 )、C(R 13 )2 and N(R 12 ), provided that Y1 and Y4, Y1 and Y5, Y4 and Y6 are not simultaneously a bond, O, S, -S(O)- or -S(O)2- and satisfy the bond valence theory; Alternatively, when Y1, Y4 and Y6 are arbitrarily selected from C(R 13 )2, two R on the same carbon atom 13 The C atom connected thereto may form a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered heterocyclic group, thereby forming a spiro ring structure with ring B; Alternatively, the ring atoms in Y1 or Y6, the ring atoms in Y4, and the substituents attached to the ring atoms form a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, a substituted or unsubstituted 4-9 membered heterocyclic group, a substituted or unsubstituted 6-10 membered aryl group, or a substituted or unsubstituted 5-10 membered heteroaryl group, thereby forming a parallel ring structure with ring B; Alternatively, X2 together with the ring atoms in Y6 and R 11 The connected ring atoms and the substituents connected to the ring atoms constitute a substituted or unsubstituted 5- or 6-membered cyclic hydrocarbon group, a substituted or unsubstituted 5- or 6-membered heterocyclic group, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- or 6-membered heteroaryl group, thereby forming a tricyclic structure with rings A and B; Ring B is a 5-, 6- or 7-membered heterocyclic ring, a benzene ring or a 5-, 6- or 7-membered heteroaromatic ring; Ring B may optionally be replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R" and substituted or unsubstituted alkoxy; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy; R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; each of the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from N and O; R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl; R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen; R 10 is selected from: H, halogen, and substituted or unsubstituted alkyl; R 11 is selected from the group consisting of: H, hydroxy, amino, halogen, substituted or unsubstituted alkyl, -NR'R", and substituted or unsubstituted alkoxy; Each R not participating in the ring 12 independently selected from the group consisting of: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-14 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; Each R not participating in the ring 13 independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C6-14 aryl-S(O)2-, substituted or unsubstituted 3-6 membered cyclic hydrocarbon group-C(O)- and NR'R"-C(O)-, or two R on the same carbon atom 13 Forming oxo (=O) or thio (=S); R 13 or R 12 After participating in the ring formation, its ring atoms may be optionally substituted by 1-3 heteroatoms selected from O, N and S; R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl; R a Selected from H and C1-C4 alkyl; in, Dashed lines indicate the presence or absence of a double bond.
2. The compound according to claim 1 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Ring A is a benzene ring or a 6-membered heteroaromatic ring.
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Ring A is a benzene ring or a pyridine ring.
4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula Ia:
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula Ib: Where, Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: When R 12 When present, they are each independently selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl-C(O)- and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: When R 12 When present, they are each independently selected from: H, acetyl, propionyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-6 membered heterocyclyl, 3-5 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkyl is optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: When R 13 When present, they are each independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cyclic hydrocarbon group-C(O)- and NR'R"-C(O)-, or two R on the same carbon atom 13 To form an oxo (=O) or thioxo (=S); wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C6 alkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cyclic hydrocarbon group-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano.
9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: When R 13 When present, they are each independently selected from: H, fluorine, chlorine, C1-C4 acyl, hydroxy, cyano, C1-C4 alkoxy, C1-C6 alkyl, C1-C4 alkyl-S(O)2- and 3-4 membered cycloalkyl-C(O)-.
10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula IIa: Where, Y4 is selected from the group consisting of: C, CH and N; Y6 is selected from the group consisting of: C, CH, and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano; n is 0, 1, 2, 3 or 4.
11. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula IIb: Where, Y1 is selected from the group consisting of: C, CH and N; Y4 is selected from the group consisting of: C, CH and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano; n is 0, 1, 2, 3 or 4.
12. The compound according to claim 10 or 11, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: Ring D is a 3-6 membered cycloalkyl, a 4-6 membered heterocyclyl, a 6-10 membered aryl or a 5-8 membered heteroaryl, wherein the 4-6 membered heterocyclyl and the 5-8 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; R 15 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0, 1 or 2.
13. The compound according to any one of claims 10 to 12, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1.
14. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula IIc: Where, Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1- C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; n is 0, 1, 2, 3 or 4.
15. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula IId: Where, Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; n is 0, 1, 2, 3 or 4.
16. The compound according to claim 14 or 15, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: Ring E is a 3-6 membered cycloalkyl or a 4-6 membered heterocyclic group, wherein the 4-6 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, C1-C4 alkyl, hydroxyl and acetyl; n is 0 or 1.
17. The compound according to any one of claims 14 to 16, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Ring E is cyclopropane, cyclobutane, cyclopentane, cyclohexane, oxetanyl, oxolanyl, tetrahydropyranyl, azetidinyl, azopentanyl or piperidinyl; R 16 is selected from H, fluorine, methyl, ethyl, hydroxyl and acetyl; n is 0 or 1.
18. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound of formula I has the structure shown in the following formula IIe: Where, X2 is C; Y6 is selected from the group consisting of: C, CH, and N; Ring F is a 5- or 6-membered cycloalkyl, a 5- or 6-membered heterocyclyl, a phenyl group, or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heterocyclyl group or the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S; R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl -C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; and n is 0, 1, 2 or 3.
19. The compound of claim 18 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: Ring F is phenyl or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heteroaryl group contains 1, 2 or 3 heteroatoms selected from O, N and S; and / or R 15 Selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxyl, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl, and n is 0, 1 or 2.
20. The compound of claim 18 or 19, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: Ring F is a 5-membered heteroaryl group, wherein the 5-membered heteroaryl group contains 1 or 2 heteroatoms selected from O and N; and / or R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1.
21. The compound according to any one of claims 18 to 20, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Ring F is pyrrolyl, furyl, pyrazolyl, imidazolyl, oxazolyl or isoxazolyl.
22. The compound of claim 10 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: The compound of formula IIa has the structure shown in the following formula IIIa: Where, D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, S(O), S(O)2, N, NR e , (CR f ) p , (CR f R g ) p , C(O)-NRe, N-NR e , CR f -NR e , and D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ; The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory; Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally replaced by 1, 2 or substituted with 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g forming an oxo (=O) or thio (=S) group; and Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
23. The compound of claim 11 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: The compound of formula IIb has the structure shown in the following formula IIIb: Where, D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, S(O), S(O)2, N, NR e , (CR f ) p , (CR f R g ) p , C(O)-NR e , N-NR e , CR f -NR e , and D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ; The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory; Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g forming an oxo (=O) or thio (=S) group; and Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
24. The compound of claim 22 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: The compound of formula IIIa has the structure shown in the following formula IVa: Where, Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
25. The compound of claim 23 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: The compound of formula IIIb has the structure shown in the following formula IVb: Where, Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 selected from The heteroatoms are N and O; and ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing heterocyclic group.
26. The compound of claim 18 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: The compound of formula IIe has the structure shown in the following formula IVc: Where, Y7, Y8 and Y9 are independently selected from: a bond, O, S, S(O), S(O)2, N, NR e , CR f and CR f R g , provided that at most one of Y7, Y8 and Y9 is a bond, Y7 and Y8, Y8 and Y9 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory, Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S); Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
27. The compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R1 is -C(O)NR'R".
28. The compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R1 is -C(O)NHR'; wherein R' is selected from H, C1-C4 alkyl and C3-C6 cycloalkyl.
29. The compound according to any one of claims 1 to 28, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R1 is -C(O)NH2.
30. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is -C(O)NHCH3 and 31. The compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R2 is selected from H, halogen, C1-C4 alkyl and C1-C4 alkoxy.
32. The compound of any one of claims 1 to 31 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R2 is selected from H, halogen and methoxy.
33. The compound of any one of claims 1 to 32, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R2 is halogen.
34. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R2 is selected from fluorine and chlorine.
35. The compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R2 is fluorine.
36. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R3 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
37. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R3 is selected from substituted or unsubstituted phenyl and substituted or unsubstituted pyridyl.
38. The compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R3 is phenyl, fluorophenyl or pyridyl.
39. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 and R5 are each independently selected from: H and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S.
40. The compound of any one of claims 1 to 39, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 and R5 are each independently selected from the group consisting of: H and substituted or unsubstituted C1-C4 alkyl.
41. The compound of any one of claims 1 to 40, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 and R5 are each independently selected from the group consisting of: H and C1-C3 alkyl.
42. The compound of any one of claims 1 to 41 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R4 and R5 are each independently selected from: H and methyl.
43. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 and R5 are both H.
44. The compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R7 and R8 are each independently selected from the group consisting of H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C2-C4 alkenyl and substituted or unsubstituted C2-C4 alkynyl.
45. The compound of any one of claims 1 to 44, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, methyl, and methoxy.
46. The compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R7 and R8 are each independently selected from fluorine and chlorine.
47. The compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R7 is chlorine, and R8 is fluorine.
48. The compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R9 is selected from H, C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen.
49. The compound of any one of claims 1 to 48, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R9 is selected from H, methyl, methoxy, hydroxy and F.
50. The compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R9 is H.
51. The compound of any one of claims 1 to 50, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R 10 Selected from: H, halogen and C1-C4 alkyl.
52. The compound of any one of claims 1 to 51 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: R 10 Selected from: H, F and methyl.
53. The compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R 10 For H.
54. The compound of any one of claims 1 to 53, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy, wherein R' and R" are independently selected from C1-C4 alkyl.
55. The compound of any one of claims 1 to 54, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
56. The compound of any one of claims 1 to 55, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R 11 For H.
57. The compound of any one of claims 1 to 56, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 is C.
58. The compound of any one of claims 1 to 56, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 is N.
59. The compound of any one of claims 1 to 58, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: X3 is C.
60. The compound of any one of claims 1 to 58, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: X3 is N.
61. The compound of any one of claims 1 to 60, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: Y5 is selected from the group consisting of: a bond, O, S, -S(O)-, N, CH2, CH, -C(O)-, -CH(OH)-, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-.
62. The compound of any one of claims 1 to 61 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Y5 is O.
63. The compound of any one of claims 1 to 61 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Y5 is CH or CH2.
64. The compound of any one of claims 1 to 61 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Y5 is NH or N.
65. The compound of any one of claims 1 to 64, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: Y6 is selected from: a bond, O, S, -S(O)-, -S(O)2-, N, CH, -C(O)-, CH2, NH, -N(CH3)-, -N(C2H4OH)-, -N(C(O)CH3)-, -N(C(O)C2H5)-, -OCH2-, -NHCH2-, -N(CH3)CH2- and -CH2CH2-.
66. The compound of any one of claims 1 to 65, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: Y1 and Y4 are independently selected from the group consisting of a bond, O, N, NH, -N(CH3)-, CH, CH2 and -CH(CH3)-, and Y1 and Y4 are not a bond or O at the same time.
67. The compound of any one of claims 1 to 66, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R6 is selected from: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl, substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group.
68. The compound of any one of claims 1 to 67, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, -S(O)2-C1-C4 alkyl optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from: C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxyl, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl.
69. The compound of any one of claims 1 to 68, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R6 is -LWZ, wherein L is a bond or a substituted or unsubstituted C1-C4 alkyl group; W is a bond, a substituted or unsubstituted C1-C4 alkyl group, a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, a substituted or unsubstituted 6-14 membered aryl group, a substituted or unsubstituted 5-10 membered heteroaryl group, a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged ring group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, a substituted or unsubstituted 6-1 A 2-membered spirocyclic group or a substituted or unsubstituted 6-12-membered spiroheterocyclic group; Z is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl, -S(O)2-C1-C4 alkyl, -S(O)2-NR'R", -S(O)2-NH2, cyano, -C(O)-C1-C4 alkyl, -O-3-8 membered cycloalkyl or -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently H or C1-C4 alkyl.
70. The compound of claim 69 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: The -LWZ is selected from: , where the wavy lines indicate the locations of bond connections.
71. The compound of any one of claims 1 to 70, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group which is optionally substituted by 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy.
72. The compound of any one of claims 1 to 71 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the locations of key connections.
73. The compound of any one of claims 1 to 72, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R4 or R5 together with R6 and the atoms to which they are attached form a radical optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy.
74. The compound of any one of claims 5 and 24-26, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Ring C is a 4-9 membered monocyclic or cyclic heterocyclic group optionally substituted by 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy.
75. The compound of any one of claims 5, 24-26 and 74, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: Ring C is optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the locations of key connections.
76. The compound of any one of claims 5, 24-26, and 74-75, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug, or metabolite thereof, wherein: Ring C is optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy 77. The compound of any one of claims 1 to 76, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: The ring A, ring B and their substituents together form any of the following groups: Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 11 is H, hydroxy, -NR'R", halogen or C1-C4 alkyl; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f Selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl; the wavy line indicates the position of the bond connection.
78. The compound of any one of claims 1 to 77, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: R1 is cyano, -C(O)NH2 or -C(O)NHCH3; R2 is H or F; R 11 H; R e R is selected from the group consisting of H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2(CH3)OH, acetyl, propionyl and cyclopropionyl; f Selected from H, F, Cl, hydroxy, cyano, -NH2, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, methoxy, methyl, ethyl, cyclopropyl and cyclobutyl.
79. The compound of any one of claims 1 to 78, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: R1 is -C(O)NH2 or -C(O)NHCH3; R2 is F; R 11 H; R e is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, -CH2CH2OH, -CH2CH2(CH3)OH, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, cyclopropyl, and acetyl; R f Selected from H, F, Cl, hydroxy, cyano, -NH2, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, methoxy and methyl.
80. The compound of any one of claims 1 to 76, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The ring A, ring B and their substituents together form any of the following groups: Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 11 H, hydroxyl, -NR'R", Halogen or C1-C4 alkyl; R 14 is H, halogen or C1-C4 alkyl; n is 0, 1 or 2; R 16 is selected from H, hydroxy, halogen and C1-C4 alkyl; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f Selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; the wavy line indicates the position of the bond connection.
81. The compound of any one of claims 1-76 and 80, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is cyano, -C(O)NH2 or -C(O)NHCH3; R2 is H or F; R 11 H; R 14 is H or methyl; n is 0, 1 or 2; R 16 is H, hydroxyl or methyl; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2(CH3)OH, acetyl, propionyl and cyclopropionyl; f Selected from H, F, Cl, hydroxy, cyano, -NH2, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, methoxy, methyl, ethyl, cyclopropyl and cyclobutyl.
82. The compound of any one of claims 1-76 and 80-81, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is -C(O)NH2 or -C(O)NHCH3; R2 is F; R 11 H; R 14 H; R 16 H; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, cyclopropyl, -CH2CH2OH, -CH2CH2(CH3)OH and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, -CH2OH, -(CH2)2OH, -(CH2)2OCH3 and methyl.
83. The compound of any one of claims 1 to 76, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The ring A, ring B and their substituents together form any of the following groups: Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 14 is H, halogen or C1-C4 alkyl; n is 0, 1 or 2; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f Selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H and C1-C4 alkyl; the wavy line indicates the position of the bond connection.
84. The compound of any one of claims 1-76 and 83, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is cyano, -C(O)NH2 or -C(O)NHCH3; R2 is H or F; R 14 is H or methyl; n is 0, 1 or 2; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, ethyl, cyclopropyl, cyclobutyl, -CH2CH2OH, -CH2CH2(CH3)OH, acetyl, propionyl and cyclopropionyl; f Selected from H, F, Cl, hydroxy, cyano, -NH2, methoxy, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, methyl, ethyl, cyclopropyl and cyclobutyl.
85. The compound of any one of claims 1 to 84, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: X2 is selected from: C and N; X3 is selected from: C and N; Y5 and Y6 are independently selected from the group consisting of: O, S, N, -S(O)-, -S(O)2-, CH(R 13 )、C(R 13 )2、C(R 13 )、-OCH2-、-N(R 12 )CH2-, -CH2CH2- and N(R 12 ); and Y5 and Y6 are not bonds at the same time; Y1 is selected from the group consisting of: a bond, O, N, CH, CH2, NH, CH(R 13 )、C(R 13 )2 and N(R 12 ); Y4 is selected from the group consisting of: a bond, O, N, CH, CH2, NH, CH(R 13 )、C(R 13 )2 and N(R 12 ); Ring B may optionally be replaced by one or more unannulated R 13 and / or R 12 In addition to substitution, it may be further optionally substituted by 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; Each R not participating in the ring 12 independently selected from H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 alkyl; said C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R not participating in the ring 13 independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-; said C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano, or two R on the same carbon atom are 13 Forming oxo (=O) or thio (=S); R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
86. The compound of any one of claims 1 to 85, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: X2 is selected from: C and N; X3 is selected from: C and N; Y5 is selected from the group consisting of: O, S, -S(O)-, -S(O)2-, N, CH2, CH, -C(O)-, NH, and -N(CH3)-; Y6 is selected from the group consisting of: O, S, -S(O)-, -S(O)2-, N, CH2, CH, -C(O)-, NH and -N(CH3)-; Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-; Y4 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-; H on ring B may be further optionally substituted with 1, 2 or 3 substituents selected from hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy; R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
87. The compound of claim 10 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 is selected from: C and N; X3 is selected from: C and N; Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-; Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; Y4 is selected from: C, CH or N; Y6 is selected from: C, CH or N; R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cyclic hydrocarbon group, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted substituted or unsubstituted 6-12 membered spiroheterocyclyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
88. The compound of claim 87 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic Heterocyclyl having 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxy and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
89. The compound of claim 11 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 and X3 are C; Y1 is selected from the group consisting of: C, CH and N; Y4 is selected from the group consisting of: C, CH and N; Y5 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, NH, -N(CH3)-, CH2, -CH(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; Y6 is selected from: bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, CH2, CH, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2- and -CH2CH2-; and Y5 and Y6 are not bonds at the same time; R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
90. The compound of claim 89 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
91. The compound of claim 14 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 and X3 are C; Y1 is selected from: O or CH2; Y5 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-; Y6 is selected from the group consisting of: a bond, O, S, N, CH2, CH, NH, and -N(CH3)-; R 16 is selected from halogen, C1-C4 alkyl, hydroxy, C1-C4 acyl and C1-C4 alkoxy; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
92. The compound of claim 91 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, and its substituents are 1, 2 or 3 selected from: halogen, hydroxyl, cyano, -NR'R", -S(O)2- NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy optionally substituted with 1, 2 or 3 groups selected from halogen, hydroxy and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
93. The compound of claim 15 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 and X3 are C; Y4 is selected from: O or CH2; Y5 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-; Y6 is selected from the group consisting of: a bond, O, S, N, CH2, CH, NH, and -N(CH3)-; R 16 is selected from halogen, C1-C4 alkyl, hydroxy, C1-C4 acyl and C1-C4 alkoxy; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1- C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
94. The compound of claim 93 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, Substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, which has 1, 2 or 3 substituents selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C(O)-C1-C4 alkyl and optionally substituted by 1, 2 or 3 substituents selected from: or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl substituted with 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
95. The compound of claim 18 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: Y1, Y4 and Y5 are independently selected from the group consisting of: O, CH, CH2, -CH(CH3)-, N, NH and -N(CH3)-; Ring F is phenyl or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heteroaryl group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 15 Selected from: H, fluorine, chlorine, acetyl, hydroxyl, C1-C4 alkoxy, cyano, -NR'R", NR'R"-C(O)-, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl; R' and R" are each independently selected from H and C1-C4 alkyl; n is 0 or 1; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
96. The compound of claim 95 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, a substituted or unsubstituted 6-12 membered spirocyclic group or a substituted or unsubstituted 6-12 membered spiroheterocyclic group, wherein The number of radicals is 1, 2 or 3 and is selected from: C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
97. The compound of claim 22, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: X2 is selected from: C and N; X3 is selected from: C and N; Y1 is selected from the group consisting of: a bond, O, NH, -N(CH3)-, CH2, and -CH(CH3)-; Y5 is selected from the group consisting of: O, S, N, CH2, CH, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; Y4 is selected from: C, CH or N; Y6 is selected from: C, CH or N; D1 is selected from: O, S, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, N, NR e 、N-NR e 、C(O)-NRe、CR f -NR e 、(CR f ) p and (CR f R g ) p ; D3 is selected from: O, S, N, NR e 、(CR f ) p and (CR f R g ) p ; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from the group consisting of: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl, and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; Here, the dotted line indicates the presence or absence of a double bond.
98. The compound of claim 97 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C(O)-C1-C4 alkyl and optionally substituted by 1, 2 or 3 groups selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1 -C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl substituted with substituents of 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, which has 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, said C1-C4 alkyl and C1-C4 alkoxy being optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein said R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
99. The compound of claim 23 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: X2 and X3 are C; Y1 is selected from the group consisting of: C, CH and N; Y4 is selected from the group consisting of: C, CH and N; Y5 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, NH, -N(CH3)-, CH, CH2, -CH(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; Y6 is selected from the group consisting of a bond, O, S, -S(O)-, -S(O)2-, -C(O)-, N, CH2, CH, -CH(CH3)-, NH, -N(CH3)-, -OCH2-, -NHCH2-, -N(CH3)CH2-, and -CH2CH2-; and Y5 and Y6 are not simultaneously a bond; D1 is selected from: O, S, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, N, NR e 、C(O)-NRe、N-NR e , CR f -NR e 、(CR f ) p and (CR f R g ) p ; D3 is selected from: O, S, N, NR e 、(CR f ) p and (CR f R g ) p ; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R3 is selected from: substituted or unsubstituted aryl; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 6-14 membered aryl, substituted or unsubstituted 5-10 membered heteroaryl and substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, substituted or unsubstituted 6-12 membered bridged ring group, substituted or unsubstituted 6-12 membered bridged heterocyclic group, substituted or unsubstituted 6-12 membered spirocyclic group and substituted or unsubstituted 6-12 membered spiroheterocyclic group; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a 4-9 membered monocyclic or cyclic heterocyclic group, a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, cyano, C1-C4 alkyl, halogen and C1-C4 alkoxy; R7 and R8 are each independently selected from: H, halogen, cyano, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, C1-C4 alkyl, C1-C4 alkoxy, hydroxyl and halogen; R 10 Selected from: H, halogen and C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, C1-C4 alkyl, -NR'R" and C1-C4 alkoxy; R' and R" are each independently selected from H and C1-C4 alkyl; Here, the dotted line indicates the presence or absence of a double bond.
100. The compound of claim 99 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: R1 is selected from the group consisting of: cyano, -C(O)NH2, -C(O)NHCH3 and R2 is selected from the group consisting of: H, fluoro and methoxy; R3 is phenyl; R4 and R5 are each independently selected from: H and C1-C4 alkyl; R6 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl or substituted or unsubstituted C2-C6 alkynyl, and its substituents are 1, 2 or 3 selected from: hydroxy, halogen, C1-C4 alkoxy optionally substituted by halogen, cyano, S(O)2-C1-C4 alkyl- optionally substituted by halogen, C1-C4 alkyl optionally substituted by halogen, -S(O)2-NR'R", -S(O)2-NH2, -C(O)-C1-C4 alkyl, -NR'-C( O)-C1-C4 alkyl and 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, halo-C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, halogen, cyano, C1-C4 alkyl-S(O)2-, hydroxy, carboxyl, -NR'R", 6-14 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl and 4-9 membered heterocyclyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 3-8 membered cyclic hydrocarbon group or a substituted or unsubstituted 4-9 membered monocyclic or cyclic heterocyclic group, and its substituents are 1, 2 or 3 selected from the group consisting of halogen, hydroxyl, cyano, -NR'R", -S(O)2-NR'R", -S(O)2-NH2, -NR'-C(O)-C1-C4 alkyl, -S(O)2-C1-C4 alkyl, C1-C4 alkyl, C1-C4 alkoxy, halo-C1-C4 alkoxy, -C(O)-C1-C4 alkyl and C1-C4 alkoxycarbonyl, and the C1-C4 alkyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 groups selected from the group consisting of halogen, hydroxyl and -NR'R", wherein the R' and R" are each independently selected from H and C1-C4 alkyl; or R6 is a substituted or unsubstituted 6-12 membered bridged cyclyl, a substituted or unsubstituted 6-12 membered bridged heterocyclyl, a substituted or unsubstituted 6-12 membered spirocyclyl or a substituted or unsubstituted 6-12 membered spiroheterocyclyl, and its substituents are 1, 2 or 3 selected from the group consisting of: C1-C4 alkyl, halo C1-C4 alkyl, C1-C4 alkoxy, halo C1-C4 alkoxy, cyano, -S(O)2-C1-C4 alkyl, hydroxy, halogen, NR'R", -S(O)2-NR'R", -S(O)2-NH2 and -NR'-C(O)-C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl; R 11 Selected from: H, hydroxy, amino, fluoro, chloro, methyl, methoxy and -NH(CH3).
101. The compound of any one of claims 1-100, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, characterized in that: Ring A and Ring B and their ring substituents together form any of the following groups: Wherein, R1 is cyano or -C(O)NR'R"; R2 is H or halogen; R 11 is H, hydroxy, -NR'R", halogen or C1-C4 alkyl; R 14 is H, halogen or C1-C4 alkyl; n is 0, 1 or 2; R 16 is selected from H, hydroxy, halogen and C1-C4 alkyl; R e R is selected from H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and substituted or unsubstituted C1-C4 acyl; f is selected from H, halogen, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted 3-6 membered cycloalkyl; preferably, the C1-C4 alkyl, C1-C4 alkoxy, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)- and C1-C4 acyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; wherein R' and R" are each independently selected from H, C1-C4 alkyl and C3-C6 cycloalkyl; the wavy line indicates the position of the bond attachment; X1 is 0; R3 is selected from phenyl which is unsubstituted or substituted with 1, 2 or 3 substituents selected from hydroxy, halogen, C1-C4 alkyl, halo-C1-C4 alkyl and C1-C4 alkoxy; R4 is selected from H and C1-C4 alkyl; R5 is selected from H and C1-C4 alkyl; R6 is selected from: H; C1-C4 alkyl, which is optionally substituted by 1, 2 or 3 substituents selected from hydroxy, halogen, C1-C4 alkoxy, cyano and -S(O)2-C1-C4 alkyl; 3-8 membered cyclic hydrocarbon group, which is optionally substituted by 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, -S(O)2-C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkoxy; 4-9 membered monocyclic or cyclic Heterocyclyl, which is optionally substituted with 1, 2 or 3 substituents selected from halogen, hydroxy, cyano, -S(O)2-C1-C4 alkyl, C1-C4 alkyl and C1-C4 alkoxy; and 6-12 membered bridged cyclyl, 6-12 membered spirocyclyl, 6-12 membered bridged heterocyclyl or 6-12 membered spiroheterocyclyl, each of which is optionally substituted with 1, 2 or 3 substituents selected from C1-C4 alkyl, C1-C4 alkoxy and cyano; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form the following group optionally substituted with 1, 2 or 3 substituents selected from H, deuterium, hydroxy, methyl, F and methoxy: The wavy lines indicate the bond connection locations; R7 and R8 are each independently selected from: H, halogen, cyano, methyl and methoxy; R9 is selected from the group consisting of: H, methyl, methoxy, hydroxyl and F; R 10 Selected from: H, F and methyl.
102. The compound of any one of claims 1-101 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, characterized in that: Ring A and Ring B and their ring substituents together form any of the following groups: Wherein, R1 is -C(O)NR'R"; R2 is F; R 11 is H, F or methyl; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2(CH3)OH, -CH2CH2OCH3 and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NR'R", methoxy, ethoxy, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, C1-C6 alkyl and 3-6 membered cyclic hydrocarbon groups, wherein R' and R" are each independently selected from H and methyl; the wavy line indicates the position of the bond attachment.
103. The compound of any one of claims 1 to 102, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, characterized in that: Ring A and Ring B and their ring substituents together form any of the following groups: Wherein, R1 is -C(O)NR'R"; R2 is F; R 11 is H, F or methyl; R 14 is H, F or methyl; n is 0, 1 or 2; R 16 is selected from H, hydroxyl and methyl; R e R is selected from H, methyl, difluoromethyl, trifluoromethyl, ethyl, fluoroethyl, difluoroethyl, trifluoroethyl, isopropyl, cyclopropyl, cyclobutyl, trifluoropropyl, oxocyclobutyl, 1,1-difluorocyclobutyl, -CH2CH2OH, -CH2CH2(CH3)OH, -CH2CH2OCH3 and acetyl; f Selected from H, F, Cl, hydroxy, cyano, -NR'R", methoxy, ethoxy, -CH2OH, -(CH2)2OH, -(CH2)2OCH3, C1-C6 alkyl and 3-6 membered cyclic hydrocarbon groups, wherein R' and R" are each independently selected from H, methyl and cyclopropyl; the wavy line indicates the position of the bond attachment.
104. The compound of any one of claims 1 to 103, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds:
105. The compound of any one of claims 1 to 104, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: wherein Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group, and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group, or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
106. The compound of any one of claims 1 to 105, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, Y4 is selected from the group consisting of: C, CH and N; Y6 is selected from the group consisting of: C, CH, and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heterocyclic groups selected from O, N and S. atom; R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano; n is 0, 1, 2, 3 or 4.
107. The compound of any one of claims 1 to 106, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, Y1 is selected from the group consisting of: C, CH and N; Y4 is selected from the group consisting of: C, CH and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; R 15 Selected from: H, halogen, oxo (=O), thio (=S), substituted or unsubstituted C1- C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl-C(O)-, substituted or unsubstituted C 1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; n is 0, 1, 2, 3 or 4.
108. The compound of any one of claims 1 to 107, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; n is 0, 1, 2, 3 or 4.
109. The compound of any one of claims 1 to 108, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, Ring E is a 3-8 membered cycloalkyl or a 4-9 membered heterocyclic group, wherein the 4-9 membered heterocyclic group contains 1, 2 or 3 heteroatoms selected from O, N and S; R 16 is selected from H, halogen, substituted or unsubstituted C1-C4 alkyl, hydroxy, substituted or unsubstituted C1-C4 acyl and substituted or unsubstituted C1-C4 alkoxy; preferably, the C1-C4 alkyl, C1-C4 acyl and C1-C4 alkoxy are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; n is 0, 1, 2, 3 or 4.
110. The compound of any one of claims 1 to 109, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, Y4 is selected from the group consisting of: C, CH and N; Y6 is selected from the group consisting of: C, CH, and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, S(O), S(O)2, N, NR e , (CR f ) p , (CR f R g ) p , C(O)-NRe, N-NR e , CR f -NR e , and D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ; The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory; Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S); Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
111. The compound of any one of claims 1 to 110, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound is selected from the following compounds: Where, Y1 is selected from the group consisting of: C, CH and N; Y4 is selected from the group consisting of: C, CH and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, S(O), S(O)2, N, NR e , (CR f ) p , (CR f R g ) p , C(O)-NRe, N-NR e , CR f -NR e , and D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ; The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory; Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g In each occurrence, independently selected from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cyclic hydrocarbon group, substituted or unsubstituted C1-C4 alkyl-S(O)2-, Substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S); Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
112. The compound of any one of claims 1 to 111 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, characterized in that: The compound is selected from the following compounds: Where, Y4 is selected from the group consisting of: C, CH and N; Y6 is selected from the group consisting of: C, CH, and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, S(O), S(O)2, N, NR e , (CR f ) p , (CR f R g ) p , C(O)-NRe, N-NR e , CR f -NR e , and D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ; The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory. Argument; Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S); Each p is independently 1, 2, 3 or 4, preferably 1 or 2; Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or an unsubstituted 6-12 membered nitrogen-containing spiroheterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing heterocyclic group.
113. The compound of any one of claims 1 to 112, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, Y1 is selected from the group consisting of: C, CH and N; Y4 is selected from the group consisting of: C, CH and N; Ring D is a 3-8 membered cycloalkyl, a 4-9 membered heterocyclyl, a 6-10 membered aryl or a 5-10 membered heteroaryl, wherein the 4-9 membered heterocyclyl and the 5-10 membered heteroaryl contain 1, 2 or 3 heteroatoms selected from O, N and S; D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f and CR f R g ; D2 is selected from: O, S, S(O), S(O)2, N, NR e , (CR f ) p , (CR f R g ) p , C(O)-NRe, N-NR e , CR f -NR e , and D3 is selected from: O, S, S(O), S(O)2, N, NR e 、(CR f ) p and (CR f R g ) p ; The condition is that D1 and D2, D1 and D3 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory; Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably Optionally, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R f is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S); Each p is independently 1, 2, 3 or 4, preferably 1 or 2; Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
114. The compound of any one of claims 1 to 113, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, X2 is C; Y6 is selected from the group consisting of: C, CH, and N; Ring F is a 5- or 6-membered cycloalkyl, a 5- or 6-membered heterocyclyl, a phenyl group, or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heterocyclyl group or the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S; R 15 Selected from: H, halogen, oxo (=O), thioxo (=S), substituted or unsubstituted C1-C4 acyl, hydroxy, substituted or unsubstituted C1-C4 alkoxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 6-10 membered aryl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-8 membered cycloalkyl, substituted or unsubstituted 3-8 membered cycloalkyl C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 6-10 membered aryl-S(O)2-, 4-9 membered heterocyclyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted by 1, 2 or 3 substituents selected from F, hydroxyl and cyano; n is 0, 1, 2 or 3.
115. The compound of any one of claims 1 to 114, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, X2 is C; Y6 is selected from the group consisting of: C, CH, and N; Ring F is a 5- or 6-membered cycloalkyl, a 5- or 6-membered heterocyclyl, a phenyl group, or a 5- or 6-membered heteroaryl group, wherein the 5- or 6-membered heterocyclyl group or the 5- or 6-membered heteroaryl group contains 1, 2, or 3 heteroatoms selected from O, N, and S; Y7, Y8 and Y9 are independently selected from: a bond, O, S, S(O), S(O)2, N, NR e , CR f and CR f R g , provided that at most one of Y7, Y8 and Y9 is a bond, Y7 and Y8, Y8 and Y9 are not O, S, -S(O)- or -S(O)2- at the same time and satisfy the bond valence theory, Each R e is independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and Substituted or unsubstituted C1-C4 alkyl, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)2-, 4-9 membered heterocyclyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-C(O)-, C1-C4 haloalkyl and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxyl and cyano; Each R f is independently selected at each occurrence from: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Each R g is independently selected at each occurrence from the group consisting of: H, halogen, substituted or unsubstituted C1-C4 acyl, hydroxy, cyano, -NR'R", substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)- and NR'R"-C(O)-, wherein R' and R" are each independently selected from the group consisting of H and C1-C4 alkyl; preferably, the C1-C4 acyl, C1-C4 alkoxy, C1-C4 alkyl, 3-6 membered cycloalkyl, C1-C4 alkyl-S(O)2- and 3-6 membered cycloalkyl-C(O)- are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Or R on the same carbon atom f and R g Forming oxo (=O) or thio (=S); Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group.
116. The compound of any one of claims 1 to 115, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound has the structure shown in the following formula XVa: Where, D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); D2 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); D3 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); D4 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); and wherein the ring in which D1, D2, D3 and D4 are located satisfies the bond valence theory and contains at most two C(=O) and three N atoms; Each R e Each occurrence is independently selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, oxo, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time; R1 is selected from: cyano and -C(O)NR'R"; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy; R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclic group; the 4-6 membered heterocyclic group contains 1 or 2 heteroatoms selected from N and O; R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkane Oxy, hydroxyl and halogen; R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl; Each p is independently 1, 2, 3 or 4.
117. The compound of any one of claims 1 to 116, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound has the structure shown in the following formula XVb: Where, D1 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); D2 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); D3 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); D4 is selected from: O, S, S(O), S(O)2, N, NR e , CR f R g , CR f and C(=O); and wherein the ring in which D1, D2, D3 and D4 are located satisfies the bond valence theory and contains at most two C(=O) and three N atoms; Each R e independently selected at each occurrence from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, oxo, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy; R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen; R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl; Ring C is a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group, or a substituted or unsubstituted 6-12 membered spiro heterocyclic group, wherein the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group, and the 6-12 membered spiro heterocyclic group each optionally further contain 1 or 2 heteroatoms selected from N and O; Ring C is preferably a substituted or unsubstituted 4-8 membered nitrogen-containing monocyclic heterocyclic group, a substituted or unsubstituted 6-12 membered nitrogen-containing spiro heterocyclic group, or a substituted or unsubstituted 6-12 membered nitrogen-containing cyclic heterocyclic group; Each p is 0, 1, 2, 3 or 4.
118. The compound of any one of claims 1 to 117, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound is selected from the following compounds: Where, D1 is selected from: N and CR f ; D4 is selected from: N and CR f , and D1 and D4 are not N at the same time; R e Selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkoxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; Each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclic group; the 4-6 membered heterocyclic group contains 1 or 2 heteroatoms selected from N and O; R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen; R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl; R h Selected from: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; 119. The compound of any one of claims 1 to 117, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug, or metabolite thereof, wherein: The compound has the structure shown in the following formula XVIb: Where, D1 is selected from: N and CR f ; D4 is selected from: N and CR f , and D1 and D4 are not N at the same time R e Selected from: H, substituted or unsubstituted C1-C4 acyl, substituted or unsubstituted C1-C4 alkane Oxy, cyano, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted 4-9 membered heterocyclyl, NR'R"-C(O)-, substituted or unsubstituted 3-6 membered cycloalkyl, substituted or unsubstituted 3-6 membered cycloalkyl-C(O)-, substituted or unsubstituted C1-C4 haloalkyl and substituted or unsubstituted C1-C4 alkyl; each R f is independently selected at each occurrence from: H, halogen, hydroxy, cyano, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C4 alkyl; preferably, the C1-C4 alkoxy and C1-C4 alkyl are optionally substituted with 1, 2 or 3 substituents selected from F, hydroxy and cyano; Y5 and Y6 are independently selected from the group consisting of: a bond, O, S, N, -S(O)-, -S(O)2-, C, CH(R 13 )、C(R 13 )2 and N(R 12 ), and Y5 and Y6 are not bonds at the same time; R2 is selected from the group consisting of: H, halogen, substituted or unsubstituted alkyl and substituted or unsubstituted alkoxy; R7 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R9 is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, hydroxyl and halogen; R 10 is selected from: H, halogen and substituted or unsubstituted C1-C4 alkyl; R 11 Selected from: H, hydroxy, amino, halogen, substituted or unsubstituted C1-C4 alkyl, -NR'R" and substituted or unsubstituted C1-C4 alkoxy; R' and R" are each independently selected from H, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl-S(O)2- and halogenated C1-C4 alkyl; R h Selected from: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; R i Selected from: H, halogen, substituted or unsubstituted C1-C4 alkyl and substituted or unsubstituted C1-C4 alkoxy; p is 1, 2, or 3. q is 0, 1, 2, 3 or 4.
120. The compound of claim 1 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopically substituted product, polymorph, prodrug or metabolite thereof, wherein: The compound is selected from the following compounds:
121. A pharmaceutical composition, characterized in that The pharmaceutical composition contains the compound according to any one of claims 1 to 120 or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope substitute, polymorph, prodrug or metabolite thereof and a pharmaceutically acceptable carrier or excipient.
122. The pharmaceutical composition of claim 121, wherein The pharmaceutical composition also contains other known anticancer agents, including but not limited to chemotherapeutic agents, such as mitotic inhibitors, such as taxane compounds (such as paclitaxel or docetaxel), vinca alkaloids (such as vincristine, vinblastine, vinorelbine or vinflunine), other anticancer agents such as metal platinum complexes (such as cisplatin, carboplatin or oxaliplatin), antimetabolites (such as pyrimidine antagonists, such as 5-fluorouracil, 5-fluoro-2-4(1H,3H)-pyrimidinedione (5FU), gemcitabine), hormonal antitumor drugs (such as flutamide), and tumor immunotherapy drugs (such as anti-PD1 antibodies).
123. Use of a compound or pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotope-substituted product, polymorph, prodrug or metabolite according to any one of claims 1 to 120, or the pharmaceutical composition according to claim 117 or 118, in the preparation of a medicament for treating or preventing a disease mediated by the interaction between YAP / TAZ and TEAD; preferably, the disease mediated by the interaction between YAP / TAZ and TEAD is a tumor, liver fibrosis and renal fibrosis; preferably, the tumor includes benign tumors and malignant tumors, in particular cancers or sarcomas, such as solid tumors or blood tumors; more preferably, the disease mediated by the interaction between YAP / TAZ and TEAD is: Mesothelioma (e.g., pleural mesothelioma (such as malignant pleural mesothelioma), peritoneal mesothelioma, pericardial mesothelioma, or mesothelioma of the vagina), cervical squamous cell carcinoma, endometrial cancer, bladder urothelial carcinoma, skin squamous cell carcinoma, poromas (e.g., benign poromas), porocarcinomas, epithelioid hemangioendothelioma, breast cancer (e.g., triple-negative breast cancer), lung cancer (e.g., non-small cell lung cancer), ovarian cancer, colorectal cancer, melanoma, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), prostate cancer, gastric cancer, esophageal cancer (e.g., esophageal cancer), squamous cell carcinoma or esophageal adenocarcinoma), liver cancer (e.g., hepatocellular carcinoma or hepatoblastoma), bile duct cancer, neurilemmoma, kidney cancer, sarcoma (e.g., rhabdomyosarcoma, embryonal rhabdomyosarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma, Kaposi's sarcoma, and soft tissue sarcomas (such as rare soft tissue sarcomas)), bone cancer, brain cancer (e.g., ependymoma (e.g., supratentorial ependymoma, such as supratentorial ependymoma in children), neuroblastoma, medulloblastoma, glioma, or meningioma), or head and neck cancer (e.g., head and neck squamous cell carcinoma).
124. The compound represented by formula Ya, Where, X1 is selected from: O and NR a ; R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered Each spiroheterocyclyl group optionally further contains 1 or 2 heteroatoms selected from N and O; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl; R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen; R 10 Selected from: H, halogen and substituted or unsubstituted alkyl.
125. A method for producing a compound represented by formula Ya, comprising the following steps: (i) palladium-catalyzed borate coupling under alkaline conditions to convert the halogen Hal1 in formula Ya-1 to QBQ to obtain Ya-2; (ii) converting Ya-2 into the potassium trifluoroborate salt of Ya-3 in an organic solvent at room temperature; (iii) using a chlorination agent to convert Ya-3 into Ya under acid catalysis in an organic solvent, Where, X1 is selected from: O and NR a ; R a Selected from H and C1-C4 alkyl; R3 is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocyclic; R4 and R5 are each independently selected from: H, halogen and substituted or unsubstituted alkyl; or R4 and R5 and the carbon atom to which they are attached form a 3-6 membered substituted or unsubstituted ring, the ring optionally containing 1, 2 or 3 heteroatoms selected from O, N and S; R6 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; Alternatively, R4 or R5 together with R6 and the atoms to which they are attached form a substituted or unsubstituted 4-12 membered monocyclic or cyclic heterocyclic group, a substituted or unsubstituted 6-12 membered bridged heterocyclic group or a substituted or unsubstituted 6-12 membered spiro heterocyclic group; each of the 4-12 membered monocyclic or cyclic heterocyclic group, the 6-12 membered bridged heterocyclic group and the 6-12 membered spiro heterocyclic group optionally further contains 1 or 2 heteroatoms selected from N and O; R8 is selected from the group consisting of: H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl; R9 is selected from the group consisting of: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxy and halogen; R 10 is selected from: H, halogen, and substituted or unsubstituted alkyl; Hal1 is a halogen; QBQ is boric acid or a boric acid ester; Pg is a nitrogen protecting group.
126. A compound represented by formula Za, In the formula, Pg is a nitrogen protecting group, preferably Boc.
127. A method for producing a compound represented by formula Za, comprising the following steps: (i) palladium-catalyzed borate coupling under alkaline conditions to convert the halogen Hal1 of formula Za-1 to QBQ to obtain Za-2; (ii) adding potassium bifluoride aqueous solution to convert QBQ into potassium trifluoroborate in an organic solvent at room temperature to obtain Za-3; (iii) using a chlorination agent to convert Za-3 into Za under acid catalysis in an organic solvent, In the formula, Hal1 is a halogen; QBQ is boronic acid or boronic ester; and Pg is a nitrogen protecting group.
